BioSig (BSGM) S-1 20 May 15 2015 Q1 IPO registration Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	S-1
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		13,634,961
Amendment Flag	FALSE
Entity Central Index Key	1530766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash	$2,059,328	$239,781	$302,187
Prepaid expenses	159,768	75,537	0
Total current assets	2,219,096	315,318	302,187
Property and equipment, net	12,844	13,020	24,866
Other assets:
Deposits	25,000	25,000	25,000
Total assets	2,256,940	353,338	352,053
Current liabilities:
Accounts payable and accrued expenses, including $14,605, $40,293 and $92,308 to related parties as of March 31, 2015, December 31, 2014 and December 31, 2013, respectively	320,871	554,026	819,330
Stock based payable	646,066	226,305	0
Advances, related party	0	0	30,781
Liability to placement agent	0	0	52,800
Dividends payable	456,964	445,069	414,967
Warrant liability	4,097,444	0	0
Derivative liability	1,242,590	0	0
Total current liabilities	6,763,935	1,225,400	3,017,501
Series C 9% Convertible Preferred stock, 2,461, 2,711 and 2,781 shares issued and outstanding liquidation preference of $2,461,000, $2,711,000 and $2,781,000 as of March 31, 2015, December 31, 2014 and December 31, 2013, respectively, net of debt discount of $-0- and $483,893 as of December 31, 2014 and 2013, respectively	2,461,000	2,711,000	2,297,107
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	0	0	0
Common stock, $0.001 par value, authorized 50,000,000 shares, 13,159,694, 11,179,266 and 8,412,101 issued and outstanding as of March 31, 2015, December 31, 2014 and December 31, 2013, respectively	13,160	11,179	8,412
Additional paid in capital	18,852,156	19,186,163	9,036,038
Accumulated deficit	-25,833,311	-22,780,404	-14,007,005
Total stockholders' deficit	-6,967,995	-3,583,062	-4,962,555
Total liabilities and stockholders' deficit	2,256,940	353,338	352,053
Series A Preferred Stock [Member]
Current liabilities:
Redeemable Preferred Stock	0	0	884,601
Series B Preferred Stock [Member]
Current liabilities:
Redeemable Preferred Stock	$0	$0	$815,022

BALANCE_SHEETS_Parentheticals

BALANCE SHEETS (Parentheticals) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounts payable and accrued expenses, related parties (in Dollars)	$14,605	$40,293	$92,308
Preferred stock, par value (in Dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000	50,000,000
Common stock, shares issued	13,159,694	11,179,266	8,412,101
Common stock, shares outstanding	13,159,694	11,179,266	8,412,101
Series A Preferred Stock [Member]
Preferred stock, shares issued		184.4	184.4
Preferred stock, shares outstanding			184.4
Preferred stock, liquidation preference (in Dollars)			922,000
Preferred stock, debt discount (in Dollars)			37,399
Preferred stock, shares authorized	200	200	200
Series B Preferred Stock [Member]
Preferred stock, shares issued		177.5	177.5
Preferred stock, shares outstanding			177.5
Preferred stock, liquidation preference (in Dollars)			887,500
Preferred stock, debt discount (in Dollars)			72,478
Preferred stock, shares authorized	600	600	600
Series C Preferred Stock [Member]
Preferred stock, shares issued	2,461	2,711
Preferred stock, shares outstanding	2,461	2,711
Preferred stock, debt discount (in Dollars)		0	483,893
Preferred stock, Series C %	9.00%	9.00%	9.00%
Preferred stock, shares issued	2,461	2,711	2,781
Preferred stock, shares outstanding	2,461	2,711	2,781
Preferred stock, liquidation preference (in Dollars)	$2,461,000	$2,711,000	$2,781,000
Preferred stock, shares authorized	4,200	4,200	4,200

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Operating expenses:
Research and development	$302,079	$122,151	$547,996	$992,207
General and administrative	2,746,853	601,565	7,304,440	5,229,252
Depreciation	2,860	4,435	15,809	17,059
Total operating expenses	3,051,792	728,151	7,868,245	6,238,518
Loss from operations	-3,051,792	-728,151	-7,868,245	-6,238,518
Other income (expense):
Interest income (expense)	-1,114	-1,098	-11,025	-70,061
Financing costs	0	-388,285	-593,770	-3,496,052
Loss before income taxes	-3,052,906	-1,117,534	-8,473,040	-9,804,631
Income taxes (benefit)	0	0	0	0
Net loss	-3,052,906	-1,117,534	-8,473,040	-9,804,631
Preferred stock dividend	-79,395	-84,024	-300,359	-297,215
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	($3,132,301)	($1,201,558)	($8,773,399)	($10,101,846)
Net loss per common share, basic and diluted (in Dollars per share)	($0.26)	($0.14)	($0.91)	($1.23)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	12,256,418	8,482,710	9,650,275	8,187,648

STATEMENT_OF_STOCKHOLDERS_DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT (USD $)	Stock Issued for Services [Member]	Stock Issued for Services [Member]	Warrant [Member]	Warrant [Member]	Warrant [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series C Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	Series B Preferred Stock [Member]	President [Member]	President [Member]	President [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during Development Stage [Member]	Bridge Loan [Member]	Embedded Derivative Financial Instruments [Member]	Total
	Additional Paid-in Capital [Member]		Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]		Bridge Loan [Member]		Bridge Loan [Member]	Embedded Derivative Financial Instruments [Member]
Beginning Balance at Dec. 31, 2012																			$8,166			$833,647	($3,905,159)			($3,063,346)
Beginning Balance (in Shares) at Dec. 31, 2012																			8,166,238
Common stock issued for services		44,751																	22			44,729				44,751
Common stock issued for services (in Shares)		21,412																	21,412
Common stock issued in settlement and payment of debt															93	228,415	228,508	9		18,668				18,677
Common stock issued in settlement and payment of debt (in Shares)															93,061			8,941
Sale of common stock																			122			247,052	247,174
Sale of common stock (in Shares)																			122,449							122,449
Fair value of vested options																						3,247,187				3,247,187
Preferred stock dividend																							-297,215			-297,215
Net loss																							-9,804,631			-9,804,631
Beneficial conversion feature in connection with note payable																						20,000				20,000
Beneficial conversion feature and warrants issued in connection with the Series C Preferred Stock																						2,404,830				2,404,830
Fair value of warrants issued	916,677	916,677					1,074,833	1,074,833
Ending Balance at Dec. 31, 2013																			8,412			9,036,038	-14,007,005			-4,962,555
Ending Balance (in Shares) at Dec. 31, 2013																			8,412,101							8,412,101
Common stock issued for services																			654			1,634,346				1,635,000
Common stock issued for services (in Shares)																			654,000
Common stock issued in settlement and payment of debt																			26			64,974				65,000
Common stock issued in settlement and payment of debt (in Shares)																			26,000
Common stock issued upon conversion of preferred stock and accrued dividends						59	88,841	88,900	578	1,062,753	1,063,331	494	997,032	997,526
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)						59,267			577,901			493,818
Donated capital																						87,500				87,500
Sale of common stock																			956			1,968,454				1,969,410
Sale of common stock (in Shares)																			956,179							956,179
Fair value of vested options																						4,193,425				4,193,425
Preferred stock dividend																							-300,359			-300,359
Net loss																							-8,473,040			-8,473,040
Fair value of warrants issued																						52,800				52,800
Ending Balance at Dec. 31, 2014																			11,179			19,186,163	-22,780,404			-3,583,062
Ending Balance (in Shares) at Dec. 31, 2014																			11,179,266							11,179,266
Common stock issued for services																			370			928,530				928,900
Common stock issued for services (in Shares)																			370,000
Reclassify fair value of derivative liability from equity				-4,097,444	-4,097,444																-1,242,590				-1,242,590
Common stock issued upon conversion of preferred stock and accrued dividends						212	317,288	317,500
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)						211,668
Sale of common stock																			1,399			3,040,814				3,042,213
Sale of common stock (in Shares)																			1,398,760
Fair value of vested options																						798,789				798,789
Preferred stock dividend																						-79,395				-79,395
Net loss																							-3,052,906			-3,052,906
Ending Balance at Mar. 31, 2015																			$13,160			$18,852,156	($25,833,311)			($6,967,995)
Ending Balance (in Shares) at Mar. 31, 2015																			13,159,694							13,159,694

STATEMENT_OF_STOCKHOLDERS_DEFI1

STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Series C Preferred Stock [Member] | Common Stock [Member]
Conversion of preferred stock at	$1.50	$1.50
Series A Preferred Stock [Member] | Common Stock [Member]
Conversion of preferred stock at		$1.84
Series B Preferred Stock [Member] | Common Stock [Member]
Conversion of preferred stock at		$2.02
Common Stock [Member] | Bridge Loan [Member]
Common stock issued at			$2.09

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($3,052,906)	($1,117,534)	($8,473,040)	($9,804,631)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	2,860	4,435	15,809	17,059
Amortization of debt discount	0	388,285	593,770	2,441,220
Equity based compensation	1,634,714	343,837	5,743,425	3,305,063
Fair value of warrants issued in connection with Series C preferred stock modifications	0	0	0	1,074,833
Fair value of warrants issued for services	0	0	0	837,243
Changes in operating assets and liabilities:
Prepaid expenses	8,744	-3,924	8,715	20,000
Accounts payable	-233,155	-119,856	-110,844	349,809
Stock based payable	419,761	0	226,305	0
Deferred rent payable	0	-1,006	-1,212	-3,055
Net cash used in operating activities	-1,219,982	-505,763	-1,997,072	-1,762,459
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	-2,684	0	-3,963	-11,716
Net cash used in investing activity	-2,684	0	-3,963	-11,716
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from the sale of Series C preferred stock and warrants	0	0	0	1,768,410
Proceeds from sale of common stock	3,042,213	229,222	1,969,410	299,974
Payments of related party notes	0	0	0	-30,000
Net repayments of related party advances	0	-20,281	-30,781	13,741
Net cash provided by financing activities	3,042,213	208,941	1,938,629	2,052,125
Net (decrease) increase in cash and cash equivalents	1,819,547	-296,822	-62,406	277,950
Cash and cash equivalents, beginning of the period	239,781	302,187	302,187	24,237
Cash and cash equivalents, end of the period	2,059,328	5,365	239,781	302,187
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	1,115	1,098	0	0
Cash paid during the period for income taxes	0	0	0	0
Non cash investing and financing activities:
Convertible bridge notes payable exchanged for preferred shares	0	0	0	600,000
Related party donated capital	0	0	87,500	0
Stock Issued for Services [Member]
Non cash investing and financing activities:
Common stock issued	0	0	85,000	0
Stock Issued for Settlement of Accounts Payable [Member]
Non cash investing and financing activities:
Common stock issued	0	0	65,000	0
Stock Issued for Settlement of Related Party Note and Advances Payable [Member]
Non cash investing and financing activities:
Common stock issued	0	0	0	228,508
Stock issued for Settlement of Accrued Interest [Member]
Non cash investing and financing activities:
Common stock issued	0	0	0	18,677
Series A Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	0	0	1,063,331	0
Series B Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	0	0	997,526	0
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	317,500	0	88,900	0
Fair Value of Derivative And Warrant Liability [Member]
Non cash investing and financing activities:
Reclassify fair value of derivative and warrant liability from equity	$5,440,034	$0	$0	$0

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES					NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.					A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows.
	Business and organization
						Business and organization
	BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
						BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
	Interim Financial Statements
						Revenue Recognition
	The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
						The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
	The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements.
						Use of estimates
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015.
						The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets and assumptions used in the fair value of stock-based compensation.
	Basis of presentation
						Concentrations of Credit Risk
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at March 31, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
						Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
						Prepaid Expenses
	Use of estimates
						From time to time, the Company issues shares of its common stock for services to be performed.  The fair value of the common stock is determined at the date of the contract for services and is amortized ratably over the term of the contract.  As of December 31, 2014 and 2013, prepaid expenses relating to stock based payments were $56,667 and $-0-, respectively.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
						Property and Equipment
	Fair Value of Financial Instruments
						Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
	Derivative Instrument Liability					Long-Lived Assets
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.					The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.  Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
	Research and development costs					Fair Value of Financial Instruments
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $302,079  and $122,151 for the three months ended March 31, 2015 and 2014, respectively.					The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
	Income Taxes					Research and development costs
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.					The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $547,996  and $992,207 for the years ended December 31, 2014 and 2013, respectively.
	Net Income (loss) Per Common Share					Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.					The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of March 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.					The computation of basic and diluted loss per share as of December 31, 2014 and 2013 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:					Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,			2014		2013
		2015		2014		Series A convertible preferred stock		-		501,089
	Series A convertible preferred stock		-		501,089	Series B convertible preferred stock		-		451,726
	Series B convertible preferred stock		-		451,726	Series C convertible preferred stock		1,807,333		1,330,627
	Series C convertible preferred stock		1,640,667		1,854,019	Options to purchase common stock		5,990,190		2,990,977
	Options to purchase common stock		6,205,190		2,990,977	Warrants to purchase common stock		5,113,990		2,717,258
	Warrants to purchase common stock		7,561,820		4,353,831	Totals		12,911,513		7,991,667
	Totals		15,407,677		10,151,642
						Income Taxes
	Stock Based Compensation					The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.					Stock Based Compensation
	As of March 31, 2015, the Company had 6,205,190 options outstanding to purchase shares of common stock, of which 4,130,240 were vested.					The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.					As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
	Registration Rights					As of December 31, 2013, the Company had 2,990,977 options outstanding to purchase shares of common stock, of which 1,675,658 were vested.
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements.					Registration Rights
	Recent Accounting Pronouncements					The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense for the liability under the registration rights agreements.
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.					Recent Accounting Pronouncements
						There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.

GOING_CONCERN_MATTERS

GOING CONCERN MATTERS	12 Months Ended
	Dec. 31, 2014
Going Concern Disclosure [Abstract]
Going Concern Disclosure [Text Block]	NOTE 2 – GOING CONCERN MATTERS
	The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during the years ended December 31, 2014 and 2013, the Company incurred net losses attributable to common stockholders of $8,773,399 and $10,101,846, respectively and used $1,997,072 in cash for operating activities for the year ended December 31, 2014. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time.
	The Company's existence is dependent upon management's ability to develop profitable operations. The Company completed financing subsequent to the date of these financial statements (See Note 16). However additional capital will be needed to continue developing its products and services and there can be no assurance that the Company's efforts will be successful. There is no assurance that can be given that management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 3 – RELATED PARTY TRANSACTIONS
	The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009.  No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. The net amount outstanding at December 31, 2014 and 2013 was $-0- and $30,781, respectively.
	On December 31, 2013, as part of a private placement transaction of our common stock and warrants, (i) $228,000 of our outstanding indebtedness that was due to a related party was converted into 93,061 shares of common stock and a warrant to purchase 46,531 shares of our common stock; and (ii) we issued to a related party 122,448 shares of our common stock and a warrant to purchase 61,225 shares of our common stock for a purchase price of $300,000
	Accrued interest and expenses due related parties as of December 31, 2014 and 2013 was $40,293 and $123,089, respectively.
	During 2014, one of the Company’s board of directors forgave an outstanding obligation of $87,500 for services.  Accordingly, the Company reclassified the liability to equity as donated capital.
	During 2014, the Company issued 34,000 shares of its common stock for future services to a board member totaling $85,000 ($2.50 per share), unrelated to his services as a board member.  The fair value of the services  is amortized over the service period.  As of December 31, 2014, the unamortized portion of $56,667 is included in prepaid expenses in the accompanying balance sheet.
	During 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 debt to a board of directors’ member ($2.50 per share).
	During 2013, in connection with the amendments of the Series C 9% Convertible Preferred stock, the Company issued to Company’s president and a Director of the Company (Series C holders) an aggregate of 53,830 warrants to purchase the Company’s common stock at $2.61 per share for five years. See Note 9 below.
	The Company has informal compensation and consulting agreements with employees and outside contractors, certain of whom are also Company stockholders. The Agreements are generally month to month.  As of December 31, 2014 and 2013, total due under these agreements and related expenses were $11,250 and $-0-, respectively.
	On January 31, 2014, as part of a private placement transaction of our common stock and warrants, a related party purchased an aggregate of 24,490 shares of common stock and a warrant to purchase 12,246 shares of common stock for an aggregate purchase price of $60,000.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended							12 Months Ended
	Mar. 31, 2015							Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 2 – PROPERTY AND EQUIPMENT							NOTE 4 – PROPERTY AND EQUIPMENT
								Property and equipment as of December 31, 2014 and 2013 is summarized as follows:
	Property and equipment as of March 31, 2015 and December 31, 2014 is summarized as follows:
									2014			2013
		March 31,			December 31,			Computer equipment	$	54,900		$	50,937
		2015			2014			Furniture and fixtures		7,803			7,803
	Computer equipment	$	57,584		$	54,900		Subtotal		62,703			58,740
	Furniture and fixtures		7,803			7,803		Less accumulated depreciation		(49,683	)		(33,874	)
	Subtotal		65,387			62,703		Property and equipment, net	$	13,020		$	24,866
	Less accumulated depreciation		(52,543	)		(49,683	)
	Property and equipment, net	$	12,844		$	13,020		Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
	Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.							Depreciation expense was $15,809 and $17,059 at December 31, 2014 and 2013, respectively.
	Depreciation expense was $2,860 and $4,435 for the three months ended March 31, 2015 and 2014, respectively.

ACCOUNTS_PAYABLE_AND_ACCRUED_E

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES					NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses at March 31, 2015 and December 31, 2014 consist of the following:					Accounts payable and accrued expenses at December 31, 2014 and 2013 consist of the following:
		March 31,		December 31,			2014		2013
		2015		2014		Accrued accounting and legal	$	190,767	$	300,893
	Accrued accounting and legal	$	71,952	$	190,767	Accrued reimbursements		26,792		17,797
	Accrued reimbursements		17,305		26,792	Accrued consulting		16,334		214,481
	Accrued consulting		82,935		16,334	Accrued research and development expenses		93,407		64,670
	Accrued research and development expenses		42,409		93,407	Accrued credit card obligations		13,278		20,425
	Accrued credit card obligations		4,735		13,278	Accrued payroll		62,068		35,896
	Accrued payroll		-		62,068	Accrued liquidated damages		55,620		48,668
	Accrued liquidated damages		55,620		55,620	Accrued office and other		29,093		16,500
	Accrued office and other		5,915		29,093	Accrued settlement related to arbitration		66,667		100,000
	Accrued settlement related to arbitration		40,000		66,667		$	554,026	$	819,330
		$	320,871	$	554,026

NOTES_PAYABLE_RELATED_PARTY

NOTES PAYABLE, RELATED PARTY	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 6 – NOTES PAYABLE, RELATED PARTY
	On November 21, 2012, the Company issued an unsecured promissory note for $218,000 to the Company’s President for previously advanced funds with interest payable annually, in arrears, on each anniversary at  the short term “Applicable Federal Rate” within the meaning of Section 1274(d) of the Internal Revenue Code of 1986, as amended adjusted each anniversary date.  The promissory note matures November 21, 2021 and may be prepaid, without premium or penalty, at any time.
	In connection with the issuance of the unsecured promissory note, the Company’s President agreed not to receive payments (by voluntary prepayment, acceleration, set-off or otherwise) associated with the unsecured promissory note absent the prior written consent of the purchasers holding at least 67% interest of the preferred stock outstanding, which purchasers must include Alpha Capital Anstalt so long as Alpha Capital Anstalt holds not less than $100,000 of preferred stock. On December 31, 2013, the Company converted the promissory note and accrued interest to 93,061 shares of the Company’s common stock and 46,531 warrants to purchase the Company’s common stock at $3.67 per share for five years.
	On December 6, 2012, the Company issued an unsecured promissory note for $30,000 to a company under the control of the Company’s President for previously advanced funds, interest free and due the earlier of (i) the next financing of not less than $300,000; (ii) February 28, 2013 or (iii) occurrence of an event of default, as defined.
	During year ended December 31, 2013, the Company paid off the promissory note in full.

CONVERTIBLE_BRIDGE_NOTES

CONVERTIBLE BRIDGE NOTES	12 Months Ended
	Dec. 31, 2014
Convertible Debt Disclosure [Abstract]
Convertible Debt Disclosure [Text Block]	NOTE 7 – CONVERTIBLE BRIDGE NOTES
	In 2012, the Company issued an aggregate of $600,000 unsecured Senior Convertible Promissory Notes ($225,000 related party) with interest due at maturity at 8% per annum and may be paid, at the Company’s discretion, in cash or the Company’s common stock.  The Notes, together with unpaid accrued interest, if any, is due upon written notice by the majority in interest of the holders on or after February 15, 2014 or (ii) upon the occurrence of an event of default, as defined.   The Notes may be prepaid in whole or in part prior to the maturity date at the Company’s discretion.
	The Convertible Bridge Notes and any accrued and unpaid interest automatically converts at the earlier of (i) (A)  a completion of a transaction whereby the Company merges or consolidates with another company that has its common stock approved for quotation on any domestic national stock exchange and (B) the new entity thereafter issues and sells shares for no less than $3.0 million aggregate gross proceeds or (ii) a qualified IPO.  The Convertible Bridge Notes shall convert into the new securities issued at 95% of the purchase price of the Conversion Securities offered to investors.
	In connection with the issuance of the Senior Convertible Promissory Notes, the Company issued the right to purchase at any time, on or after the Public Financing Closing Date,(as defined above) hereof until  the fifth anniversary of the Public Financing Closing date, the number of fully paid and nonassessable shares (the “Warrant Shares”) of the Company’s common stock equal to the quotient of (a) the Warrant Coverage Amount (as defined below), divided by (b) the applicable Conversion Price  of the Notes, at the per share exercise price (the “Exercise Price”), which shall initially be, as of the Public Financing Closing Date, equal to the Initial Exercise Price (as defined below), subject to further adjustments, as defined.
	Initial Exercise Price” means one hundred twenty-five percent (125%) of the Conversion Price.
	Warrant Coverage Amount” shall be the amount obtained by multiplying (x) the Warrant Coverage Percentage by (y) the principal amount outstanding (and not including any accrued and unpaid interest) of the Note, in connection with which this Warrant is concurrently issued.
	“Warrant Coverage Percentage” shall be equal to fifty percent (50%) as defined in the Bridge Loan Agreement.
	On February 6, 2013, the Convertible Bridge Notes and the above described contingent warrants previously issued as described above were converted into 600 shares of  Series C Convertible Preferred Stock and an aggregate of 287,082 warrants to purchase the Company’s common stock at an exercise price of $2.09 per share for 5 years.  On August 7, 2013, the Company issued an aggregate of 8,941 shares of its common stock in settlement of accrued interest of $18,677.

REDEEMABLE_PREFERRED_STOCK

REDEEMABLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2014
Redeemable Preferred Stock [Abstract]
Redeemable Preferred Stock [Text Block]	NOTE 8 – REDEEMABLE PREFERRED STOCK
	Series A Preferred Stock
	In May 2011, the Board of Directors authorized the issuance of up to 200 shares of Series A Preferred Stock (the “Series A preferred stock”).
	The Series A preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on August 31, 2011 and are cumulative.  The holders of Series A preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series A preferred stock, the Company cannot, (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation.
	The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends.  If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
	The Series A preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $1.84 per share.
	On February 6, 2013, in connection with the amendment to the Series A preferred stock defining the conversion feature, the Company reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
	As of December 31, 2013, 184.4 shares of Series A preferred stock were issued and outstanding with accrued dividends of $119,355 payable on the Series A preferred stock.
	On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 577,901 shares of its common stock in exchange for all the outstanding Series A preferred stock and accrued dividends of $141,331.
	Series B Preferred Stock
	On November 28, 2011, the Board of Directors authorized the issuance of up to 600 shares of Series B Preferred Stock (the “Series B preferred stock”).
	The Series B preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on December 31, 2011 and are cumulative.  The holders of Series B preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series B preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation.
	The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends.  If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
	The Series B preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $2.02 per share.
	On February 6, 2013, in connection with the amendment to the Series B preferred stock defining the conversion feature, the Company reclassified the associated financing costs as a debt discount against the carrying value of the preferred stock.
	As of December 31, 2013, 177.5 shares of Series B preferred stock were issued and outstanding. With accrued dividends of $88,872 payable on the Series B preferred stock.
	On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 493,818 shares of its common stock in exchange for all the outstanding Series B preferred stock and accrued dividends of $110,026.

SERIES_C_9_CONVERTIBLE_PREFERR

SERIES C 9% CONVERTIBLE PREFERRED STOCK	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 4 – SERIES C 9% CONVERTIBLE PREFERRED STOCK	NOTE 9 – SERIES C 9% CONVERTIBLE PREFERRED STOCK
		On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock”).
	On January 9,  2013, the Board of Directors authorized the issuance of up to 4,200 shares of Series C Convertible Preferred Stock (the “Series C Convertible Preferred Stock”).
		The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of Series C preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation.
	The Series C convertible preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends ; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the Stated Value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative.  The holders of Series C preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation.
		Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price of $1.50 (as reset).
	Each share of Series C preferred stock is convertible, at the holder’s option, inclusive of any accrued and unpaid dividends, at conversion price of $1.50 (as reset).
		If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion price shall be reduced to equal the Base Conversion Price.  Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  During the year ended December 31, 2014, the resets provisions as described above resulted in the conversion price reset to $1.50.
	If, at any time while the Series C preferred stock is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the then conversion price (“Base Conversion Price”), then the conversion price shall be reduced to equal the Base Conversion Price.  Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  During 2014, the resets provisions as described above resulted in the conversion price reset to $1.50.
		The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity.
	The Series C preferred stock contains triggering events which would require redemption at (i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.   The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C preferred stock outside of equity.
		In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrant provides if, at any time while the warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share that is lower than the then conversion price (“base conversion price”), then the warrants outstanding will be subject anti-dilution provisions.
	In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date.  The warrant provides if, at any time while the warrant is outstanding, the Company sells or grants any option to purchase or sells or grants any right to re-price, or otherwise disposes of or issues any common stock or common stock equivalents entitling any person to acquire shares of common stock at an effective price per share that is lower than the then conversion price (“base conversion price”), then the conversion price shall be reduced to equal the Base Conversion Price.
		Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  In addition, the warrants provides for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula. During the year ended December 31, 2014, the resets provisions as described above resulted in an additional 984,674 warrants issued with an exercise price reset to $1.50 all Series C warrants..
	Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.  In addition, the warrants provides for at any time after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula. During 2014, the resets provisions as described above resulted in an additional 984,674 warrants issued with an exercise price reset to $1.50 all Series C warrants.
		In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value the conversion option ($1,303,671),  relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C stockholders.
	In accordance with ASC 470-20, the Company recognized an embedded beneficial conversion feature present in the Series C preferred stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital.  The aggregate debt discount, comprised of the relative intrinsic value the conversion option ($1,303,671),  relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590); total of $2,781,000, is amortized over one year as interest expense, the date a possible redemption feature, outside of the Company’s control, would be available to the Series C stockholders
		The Company valued the warrants in accordance with ASC 470-20 using the Black-Scholes pricing model and the following assumptions: contractual terms of 5 years, an average risk free interest rate of 0.39% to 1.40%, a dividend yield of 0%, and volatility of 123.41% to 125.33%.
	During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C 9% Convertible Preferred Stock.
		During the month of February 2013, the holders of the Convertible Bridge Notes (See Note 7) converted into 600 shares of the Company’s Series C 9% Convertible Preferred Stock.
	During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9% Convertible Preferred Stock for net proceeds of $1,814,910.
		During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C 9% Convertible Preferred Stock for net proceeds of $1,814,910.
	At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  There was no established market for the Company’s common stock.  As described in Note 6, March 31, 2015, the Company determined a market has been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities.
		During October 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
	As of March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%.
		The Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  As of December 31, 2014, the Company’ s common stock was thinly traded and there was no active trading market.
	During January 2015, the Company issued an aggregate of 42,334 shares of its commons stock in exchange for 50 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
		Series C preferred stock outstanding totaled 2,711 and 2,781 as of December 31, 2014 and 2013.  As of December 31, 2014 and 2013, the Company has accrued $445,069 and $206,740 dividends payable on the Series C preferred stock.
	During March 2015, the Company issued an aggregate of 169,334 shares of its commons stock in exchange for 200 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
		Registration Rights Agreement
	Series C preferred stock issued and outstanding totaled 2,461 and 2,711 as of March 31, 2015 and December 31, 2014, respectively.  As of March 31, 2015 and December 31, 2014, the Company has accrued $456,964 and $445,069 dividends payable on the Series C preferred stock.
		The Company entered into a Registration Rights Agreement  in connection with the sale and issuance of the Series C preferred stock.  The Company is required to file a registration statement registering for resale the  (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution,  recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.
	Registration Rights Agreement
		The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company fails to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
	The Company entered into a Registration Rights Agreement  in connection with the sale and issuance of the Series C preferred stock.  The Company is required to file a registration statement registering for resale the  (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution,  recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.
		On June 23 2014, the Company became effective and met its required filing requirement.  The Company did not meet the effectiveness obligation by November 22, 2013.  As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement.
	The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
	On June 23 2014, the Company became effective and met its required filing requirement.  The Company did not meet the effectiveness obligation by November 22, 2013.  As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement.

STOCKHOLDER_EQUITY

STOCKHOLDER EQUITY	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 6 – STOCKHOLDER EQUITY	NOTE 10 – STOCKHOLDER EQUITY
		There is not a viable market for the Company’s common stock to determine its fair value; therefore, management is required to estimate the fair value to be utilized in the determining stock based compensation costs.  In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value.  Accordingly, actual results could vary significantly from management’s estimates.
	Preferred stock
		Preferred stock
	The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2015 and December 31, 2014,  the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock and 4,200 , shares of Series C preferred stock.   As of March 31, 2015 and December 31, 2014, there were no outstanding shares of Series A and Series B preferred stock.
		The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2014 and 2013,  the Company has designated and issued 200 and 184.4 shares of Series A preferred stock, respectively, designated and issued 600 and 177.5 shares of Series B preferred stock, respectively. See Note 8.
	During January 2015, the Company issued an aggregate of 42,334 shares of its commons stock in exchange for 50 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends.
		As of December 31, 2014 and 2013, the Company designated and issued 4,200 and 2,781 shares of Series C 9% convertible preferred stock, respectively. See Note 9.
	During March 2015, the Company issued an aggregate of 169,334 shares of its commons stock in exchange for 200 shares of the Company’s Series C 9% Convertible preferred stock and accrued dividends.
		On June 23, 2014, the Company issued an aggregate of 577,901 and 493,818 shares of its common stock in exchange of all the issued and outstanding Series A and Series B preferred stock.
	As of March 31, 2015 and December 31, 2014, the Company has 2,461 and 2,711 Series C 9% Convertible Preferred Stock issued and outstanding.
		During December 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends.
	Common stock
		Common stock
	The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of March 31, 2015 and December 31, 2014, the Company has 13,159,694 and 11,179,266 shares issued and outstanding, respectively.
		The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of December 31, 2014 and 2013, the Company has 11,179,266 and 8,412,101 shares issued and outstanding, respectively.
	During the three months ended March 31, 2015, the Company issued an aggregate of 370,000 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $928,900 ($2.51 average per share).
		During the year ended December 31, 2013, the Company issued an aggregate of 21,412 shares of common stock for services rendered totaling $44,751 ($2.09 per share).
	During the three months ended March 31, 2015, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 1,398,760 shares of common stock and warrants for aggregate net proceeds of $3,042,213.
		During the year ended December 31, 2013, the Company issued an aggregate of 122,449 shares of common stock for cash rendered totaling $247,174 ($2.45 per share).
	In connection with the securities purchase agreements described above, the Company entered into a registration rights agreement whereas the Company is required to file a registration statement registering for resale the  a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c)  the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date.
		During the year ended December 31, 2014, the Company issued 654,000 shares of its common stock (net of shares exchanged) under the terms of its 2012 Equity Plan for services rendered totaling $1,635,000 ($2.50 per share).
	The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold.  If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser.
		During the year ended December 31, 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 related party debt ($2.50 per share).
	Stock based payable
		During the year ended December 31, 2014, the Company entered into a securities purchase agreement with investors pursuant to which the Company issued 956,179 shares of common stock and five-year warrants for aggregate net proceeds of $1,969,410.
	The Company is obligated to issue shares of its common stock to board members and consultants for past and future services.  The estimated liability as of March 31, 2015 and December 31, 2014 of $646,066 and $226,305 was determined based on services rendered  for past services as of March 31, 2015 and December 31, 2014, respectively.
		Stock based payable
	As of March 31, 2015, the Company is obligated to issue an aggregate of 352,500 shares of its common stock.  These shares were considered issued as of the date of obligation in determining the weighted average number of outstanding shares used in the basic loss per common share calculation.
		The Company is obligated to issue an aggregate of 417,500 shares of its common stock to consultants for past and future services.  The estimated liability as of December 31, 2014 of $226,305 ($2.50 per share) was determined based on services rendered in 2014.

OPTIONS_AND_WARRANTS

OPTIONS AND WARRANTS	3 Months Ended																12 Months Ended
	Mar. 31, 2015																Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 7 – OPTIONS AND WARRANTS																NOTE 11 – OPTIONS AND WARRANTS
																	There is not a viable market for the Company’s common stock to determine its fair value, therefore management is required to estimate the fair value to be utilized in the determining stock based compensation costs.  In estimating the fair value, management considers recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value.  Accordingly, actual results could vary significantly from management’s estimates
	On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 8,806,123,( as amended)  shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.
																	On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 8,806,123,( as amended)  shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith.
	Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan.
																	Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan.
	During the three months ended March 31, 2015, the Company granted an aggregate of 200,000 options and 370,000 stock grants to officers, directors and key consultants.
																	During the year ended December 31, 2014, the Company granted an aggregate of 3,478,498 options and 654,000 stock grants (net of shares exchanged) to officers, directors and key consultants.
	The following table presents information related to stock options at March 31, 2015:
																	A summary of the stock option activity and related information for the 2012 Plan for the year ended December 31, 2014 and 2013 is as follows:
	Options Outstanding												Options Exercisable
									Weighted																		Weighted-Average
									Average				Exercisable										Weighted-Average				Remaining				Aggregate
	Exercise				Number of				Remaining Life				Number of						Shares				Exercise Price				Contractual Term				Intrinsic Value
	Price				Options				In Years				Options				Outstanding at January 1, 2013			1,298,927			$	2.04				6.85				-
	$	1.01-2.00				834,642				4.5				541,642			Grants			1,692,050				2.09				7				-
		2.01-2.50				5,370,548				6.7				3,588,598			Exercised
						6,205,190				6.4				4,130,240			Canceled
																	Outstanding at December 31, 2013			2,990,977			$	2.05				6.02			$	-
	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2015 is as follows:																Grants			3,478,498			$	2.39				8.1			$	-
																	Exercised			-
											Weighted-Average						Canceled			(479,285	)			(2.00	)
							Weighted-Average				Remaining				Aggregate		Outstanding at December 31,2014			5,990,190			$	2.25				6.65			$	3,267,692
			Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,990,190			$	2.25				6.7				3,267,692	Vested and expected to vest at December 31, 2014			5,990,190			$	2.25				6.65			$	3,267,692
	Grants			215,000				2.47				7				-	Exercisable at December 31, 2014			3,799,559			$	2.24				5.91			$	2,111,368
	Exercised
	Canceled																The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.80 as of December 31, 2014, which would have been received by the option holders had those option holders exercised their options as of that date.
	Outstanding at March 31, 2015			6,205,190			$	2.26				6.4			$	1,098,888
	Exercisable at March 31, 2015			4,130,240			$	2.25				5.9			$	797,753	Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the years ended December 31, 2014 and 2014 was estimated using the Black-Scholes pricing model.
	The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.40 as of March 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date.																In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding.
	Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.  The fair value of stock-based payment awards during the three months ended March 31, 2015 was estimated using the Black-Scholes pricing model.																If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.
	In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding.																The Company estimated forfeitures related to option grants at a weighted average annual rate of  0% per year, as the Company does not yet have adequate historical data, for options granted during the years ended December 31, 2014 and 2013.
	If the Company’s actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the stock-based compensation expense could be significantly different from what the Company has recorded in the current period.																During the year ended December 31, 2013, the Company granted an aggregate of 1,692,050 options to purchase the Company stock in connection with the services rendered at the exercise price of $2.09 per share for a term of seven to ten years with 1,095,000 vesting immediately, 145,833 vesting over three months, 30,000 vesting over nine months, 283,300 options vesting at ratably over one year and 137,917 vesting over two years.
	The Company estimated forfeitures related to option grants at a weighted average annual rate of  0% per year, as the Company does not yet have adequate historical data, for options granted during the three months ended March 31, 2015.																The fair value of the granted options for year ended December 31, 2013 was determined using the Black Scholes option pricing model with the following assumptions:
	During the months ended March 31, 2015, the Company granted an aggregate of 215,000 options to purchase the Company stock in connection with the services rendered at the exercise prices from $2.00 to $2.50 per share for a term of seven years with 15,000 vesting immediately and 200,000 over two years at 50% for the first and second anniversary.																Dividend yield:		-0-	%
																	Volatility		110.70% to 115.03	%
	The fair value of the granted options for three months ended March 31, 2015 was determined using the Black Scholes option pricing model with the following assumptions:																Risk free rate:		1.07% to 3.04	%
																	Expected life:		7 to 10 years
	Dividend yield:			-0-	%												Estimated fair value of the Company’s common stock		$2.09
	Volatility		129.54% to 130.30		%
	Risk free rate:		1.19% to 1.79		%												The following assumptions were used in determining the fair value of options during the year ended December 31, 2014:
	Expected life:		7 years
	Estimated fair value of the Company’s common stock		$	1.99 to $2.24													Dividend yield:		-0-	%
	Estimated forfeiture rate			0	%												Volatility		119.43% to 129.88	%
																	Risk free rate:		0.48% to 2.53	%
	The fair value of all options vesting during the three months ended March 31, 2015 and 2014 of $798,789 and $343,837, respectively, was charged to current period operations.  Unrecognized compensation expense of $1,970,428 at March 31, 2015 will be expensed in future periods.																Expected life:		7 to 10 years
																	Estimated fair value of the Company’s common stock		$2.21 to $2.50
	Warrants
																	In July 2014, the Company awarded 1,265,769 of stock options to Company’s Chief Executive Officer.  The stock options have exercise price of $2.21 per share, with 45,206 options vesting immediately and 497,267 options vesting quarterly over a two year period with the remainder contingent on performance, and have an approximate fair value of $2,383,443 using the Black Scholes model.
	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:
																	In September 2014, the Company awarded an aggregate of 880,000 of stock options to certain employees and key consultants.  The stock options have exercise price of $2.50 per share, with 605,000 vested immediately, 125,000 in one year and 150,000 over a two year period, and have an approximate fair value of $1,753,616 using the Black Scholes model.
	Exercise				Number			Expiration
	Price				Outstanding			Date									In September 2014, the Company canceled an aggregate of 479,285 previously issued, unvested (contingent) options issued in July 2012 at an exercise price of $2.00 per share to a board member in exchange for issuance of 479,285 options at an exercise price of $2.50, vesting quarterly over two years and expiring 7 years from the date of issuance.  The greater of the approximate fair value of the options exchanged of $981,798 was determined using the Black Scholes option model.
	$	0.001				383,320		Jan-20
	$	1.5				3,721,518		February 2018 to September 2018									In October 2014, the Company awarded an aggregate of 853,444 stock options to certain employees and a key consultant.  The stock options have an exercise price of $2.50 per share with 841,777 vested immediately and a remainder of 11,667 based on future performance conditions, and have an approximate fair value of $1,339,151.
	$	1.84				35,076		Jan-20
	$	2.02				30,755		Jan-20									In October 2014, one of the Company’s board of directors exchanged 125,000 common shares issued in September 2014 for services and debt repayment for 163,444 stock options.  The stock options have an exercise price of $2.50, vesting immediately.  The approximate fair value of the exchange was determined to be the same.
	$	2.5				1,603,600		Jul-15
	$	2.75				228,720		August 2019 to September 2019									The following table presents information related to stock options at December 31, 2014:
	$	3.67				218,275		December 2018 to January 2019
	$	3.75				1,340,556		April 2019 to March 2020									Options Outstanding								Options Exercisable
						7,561,820																			Weighted
																									Average				Exercisable
On January 23, 2015, the Company issued an aggregate of 428,400 and 321,300 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.																Exercise				Number of				Remaining Life				Number of
																Price				Options				In Years				Options
On February 10, 2015, the Company issued an aggregate of 337,000 and 252,750 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.																$	1.01-2.00				819,642				4.7				526,642
																	2.01-2.50				5,170,548				7				3,272,917
On February 27, 2015, the Company issued an aggregate of 223,000 and 167,250 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.																					5,990,190				6.7				3,799,559
On March 31, 2015, the Company issued an aggregate of 410,360 and 307,770 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock.																The fair value of all options vesting during the year ended December 31, 2014 and 2013 of $4,193,425 and $3,247,187, respectively, was charged to current period operations.  Unrecognized compensation expense of $3,778,589 and $862,066 at December 31, 2014 and 2013, respectively, will be expensed in future periods.
A summary of the warrant activity for the three months ended March 31, 2015 is as follows:																Warrants
										Weighted-Average						The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:
						Weighted-Average				Remaining				Aggregate
		Shares				Exercise Price				Contractual Term				Intrinsic Value		Exercise			Number		Expiration
Outstanding at January 1, 2015			5,113,990			$	1.71				3.6				6,041,436	Price			Outstanding		Date
Grants			2,447,830				3.04				2.4				-	$	0.001		383,320		Jan-20
Exercised																$	1.5		3,721,518		February 2018 to September 2018
Canceled																$	1.84		35,076		Jan-20
Outstanding at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	$	2.02		30,755		Jan-20
																$	2.5		204,840		Jul-15
Vested and expected to vest at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	$	2.75		228,720		August 2019 to September 2019
Exercisable at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	$	3.67		218,275		December 2018 to January 2019
																$	3.75		291,486		April 2019 to March 2020
The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.40 as of March 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date.																			5,113,990
																On January 13, 2013, the Company issued  an aggregate of 65,831 warrants to purchase the Company stock in connection with the placement services at the exercise prices of $1.84 (35,076 warrants) and $2.02 (30,775 warrants) per share for a term of five years exercisable immediately.
																The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
																Dividend yield:			-0-	%
																Volatility			123.3	%
																Risk free rate:			0.72	%
																Expected life:		5 years
																Estimated fair value of the Company’s common stock		$	2.09
																The fair value of $115,854 was charged to operations ratably as financing costs through December 31, 2014.
																During the year ended December 31, 2013, the Company issued an aggregate of 1,516,386 warrants to purchase the Company stock in connection with the sale of the Series C 9% Convertible Preferred Stock at the exercise price of $2.61 per share for a term of five years exercisable immediately.
																During the months of July and September, 2013, the Company issued an aggregate of 622,414 warrants to purchase the Company’s stock to holders of Series C preferred stock as an inducement to amend and waive certain defined provisions of the Series C preferred stock.
																The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
																Dividend yield:			-0-	%
																Volatility			125.33	%
																Risk free rate:			1.4	%
																Expected life:		5 years
																Estimated fair value of the Company’s common stock		$	2.09
																During the year ended December 31, 2013, the fair value of $1,074,833 was charged to current period operations
																On December 31, 2013, the Company issued an aggregate of 129,307 warrants to purchase the Company’s common stock at $3.67 per share for five years in connection with the sale of the Company’s common stock.
																On January 31, 2014, the Company issued an aggregate of 64,626 warrants to purchase the Company’s common stock at $3.67 per share for five years in connection with the sale of the Company’s common stock.
																In February 2014, as described in the terms of the warrants issued in connection with the sale of the Series C preferred stock, the Company reset 2,138,800 previously issued warrants from a exercise price of $2.61 per share to $1.50.  In addition, the Company was required to increase the number of issued warrants to an aggregate total of 3,721,518 warrants.
																In April 2014, the Company issued an aggregate of 137,856 warrants to purchase the Company’s common stock at $3.75 per share for five years in connection with the sale of the Company’s common stock.
																In August 2014, the Company issued an aggregate of 135,120 warrants to purchase the Company’s common stock at $2.75 per share for five years in connection with the sale of the Company’s common stock.
																In September 2014, the Company issued an aggregate of 93,600 warrants to purchase the Company’s common stock at $2.75 per share for five years in connection with the sale of the Company’s common stock.
																In December 2014, the Company issued an aggregate of 358,470 warrants to purchase the Company’s common stock in connection with the sale of the Company’s common stock. Of the aggregate issued, 204,840 warrants are exercisable at $2.50 expiring six months from the date of issuance and 153,630 warrants exercisable at $3.75 per share expiring March 31, 2020.
																A summary of the warrant activity for the years ended December 31, 2014 and 2013 is as follows:
																										Weighted-Average
																						Weighted-Average				Remaining				Aggregate
																		Shares				Exercise Price				Contractual Term				Intrinsic Value
																Outstanding at January 1, 2013			-			$	-				-				-
																Grants			2,717,258				2.28				7				-
																Exercised
																Canceled
																Outstanding at December 31, 2013			2,717,258			$	2.28				6.02			$	-
																Grants			2,396,732			$	4.64				2.05			$	-
																Exercised			-
																Canceled			-				-
																Outstanding at December 31,2014			5,113,990			$	1.71				3.6			$	6,041,436
																Vested and expected to vest at December 31, 2014			5,113,990			$	1.71				3.6			$	6,041,436
																Exercisable at December 31, 2014			5,113,990			$	1.71				3.6			$	6,041,436
																The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s estimated market stock price of $2.80 as of December 31, 2014, which would have been received by the option holders had those option holders exercised their options as of that date.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 8 – FAIR VALUE MEASUREMENT					NOTE 12 – FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value:					The Company follows the provisions of ASC 825-10.  For financial assets and liabilities included within the scope of ASC 825-10, the Company was required to adopt the provisions of ASC 825-10 prospectively as of the beginning of Fiscal 2009.  The adoption of ASC 825-10 did not have a material impact on our consolidated financial position or results of operations.
	Level 1 – Quoted prices in active markets for identical assets or liabilities.					The Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required.  As of December 31, 2014, the Company’ s common stock was thinly traded and there was no active trading market.
	Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.					The Company determined that there were no items required to be measured at fair value on a recurring basis in the consolidated financial statements as of December 31, 2014 and 2013.
	Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.
	All items required to be recorded or measured on a recurring basis are based upon level 3 inputs.
	To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement.
	Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements.
	The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity.
	As of March 31, 2015 or December 31, 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures.
	The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 6. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 6 are that of volatility and market price of the underlying common stock of the Company.
	As of March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.
	The derivative and warrant liability as of March 31, 2015, in the amount of $1,242,590 and $4,097,444 has a level 3 classification, respectively.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2015:
		Warrant		Derivative
		Liability
	Balance, December 31, 2014	$	-	$	-
	Total (gains) losses
	Initial fair value of derivative at March 31, 2015, reclassified from equity		—		1,242,590
	Initial fair value of warrant liability at March 31, 2015, reclassified from equity		4,097,444		—
	Balance, March 31, 2015	$	4,097,444	$	1,242,590
	Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price increases for each of the related derivative instruments, the value to the holder of the instrument generally increases, therefore increasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 13 – COMMITMENTS AND CONTINGENCIES
	Operating leases
	On May 31, 2014, the Company extended its expiring three-year lease for office space in Los Angeles, California for one additional year, with monthly payments of $6,530 beginning September 1, 2014.
	Employment agreements
	On July 14, 2014, the Company’s Board Of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer.
	In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.
	In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.
	Litigation
	On January 7, 2014, David Drachman, the Company’s former chief executive officer and president, filed a statement of claim against the Company with the American Arbitration Association with respect to his resignation from his positions with us in November 2013.  Mr. Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
	During the year ended December 31, 2014, the Company settled the above claim for $100,000 with payments over six months.  As of December 31, 2014, $66,667 was outstanding.
	The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business.  Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.  There was no outstanding litigation as of December 31, 2014.

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 14 – INCOME TAXES
	At December 31, 2014, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $6,800,000, expiring in the year 2034, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company's ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.  During the year ended December 31, 2014, the Company has increased the valuation allowance from $1,400,000 to $2,300,000.
	We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns.  ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities.  Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement.  The Company had no tax positions relating to open income tax returns that were considered to be uncertain.
	The Company is required to file income tax returns in the U.S. Federal jurisdiction and in California. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2010.
	The effective rate differs from the statutory rate of 34% for due to the following:
		2014			2013
	Statutory rate on pre-tax book  loss		(34.00	)%		(34.00	)%
	Stock based compensation		23	%		11.7	%
	Financing costs		2.4	%		2.4	%
	Valuation allowance		8.6	%		19.9	%
			0	%		0	%
	The Company’s deferred taxes as of December 31, 2014 and 2013 consist of the following:
		2014			2013
	Non-Current deferred tax asset:
	Net operating loss carry-forwards	$	2,300,000		$	1,400,000
	Valuation allowance		(2,300,000	)		(1,400,000	)
	Net non-current deferred tax asset	$	-		$	-

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 9 – SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS
		Common stock:
	On April 9, 2015, the Company granted options to acquire 300,000 shares of its common stock at an exercise price of $3.99 for seven years, vesting immediately upon appointment of a new board of directors member.
		On January 13, 2015, the Company issued 42,334 shares of its Common stock upon conversion of 50 shares of Series C Preferred stock and accrued dividends.
	In April 2015, the Company issued an aggregate of 131,234 shares of its common stock in exchange for 155 shares of Series C 9% Convertible preferred stock and accrued dividends.
		In January, 2015, the Company issued an aggregate of 302,500 shares of its common stock to consultants for services . See Note 10.
	In April 2015, the Company issued 84,033 shares of its common stock in exchange for the exercise of 130,084 warrants exercisable at $1.50, on a cashless basis.
		January 2015 Private Placement
	In April 2015, the Company issued an aggregate of 200,000 shares of its common stock to board of directors for services rendered.
		On January 23, 2015, the Company entered into a securities purchase agreement with investors, pursuant to which we issued 365,200 shares of the Company’s our common stock, and "A" warrants expiring July 31, 2015 to purchase 365,200 shares of our common stock for aggregate cash proceeds of $913,000, and "B" warrants expiring March 21, 2020 to purchase 182,600 shares of our common stock for aggregate net cash proceeds of $917,480.  In connection with the private placement, the Company issued 91,300 warrants to purchase our stock in connection with the placement services at the exercise price of $3.75 per share expiring March 21, 2020 for investment banking services.
	In April 2015, the Company issued 50,000 shares of its common stock to a consultant for services rendered.
		February 2015 Private Placement
	In April 2015, the Company issued an aggregate of 10,000 shares of its common stock for the exercise of  previously issued options  at $2.09 per share.
		On February 10, 2015, the Company entered into a securities purchase agreement with investors, pursuant to which we issued 337,000 shares of the Company’s common stock, and "A" warrants expiring July 31, 2015 to purchase 337,000 shares of our common stock for aggregate cash proceeds of $842,500, and "B" warrants expiring March 21, 2020 to purchase 168,500 shares of our common stock for aggregate net cash proceeds of $731,400.  In connection with the private placement, the Company issued 84,250 warrants to purchase our stock in connection with the placement services at the exercise price of $3.75 per share expiring March 21, 2020 for investment banking services.

WARRANT_AND_DERIVATIVE_LIABILI

WARRANT AND DERIVATIVE LIABILITIES	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 5 – WARRANT AND DERIVATIVE LIABILITIES
	At the time of issuance and till March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C 9% Convertible Preferred Stock and related warrants (see Note 5) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required.  There was no established market for the Company’s common stock.   As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. .
	The Company valued the reset provisions of the Series C Preferred Stock in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Business and organization					Business and organization
	BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company is principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.					BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
	Interim Financial Statements
	The unaudited condensed interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
	The condensed balance sheet as of December 31, 2014 has been derived from audited financial statements.
	Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These condensed financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2014 filed with the Company’s Form 10-K with the Securities and Exchange Commission on February 20, 2015.
	Basis of presentation
	The Company's primary efforts are devoted to conducting research and development principally devoted to improving the quality of cardiac recordings obtained during EP studies and catheter ablation procedures. The Company has experienced net losses and negative cash flows from operations since inception and expects these conditions to continue for the foreseeable future. In addition, the Company has stockholders' deficiencies at March 31, 2015 and requires additional financing to fund future operations. Further, the Company does not have any commercial products available for sale and there is no assurance that if approval of their products is received that the Company will be able to generate cash flow to fund operations. In addition, there can be no assurance that the Company's research and development will be successfully completed or that any product will be approved or commercially viable.
	The above factors raise substantial doubt as to the Company's ability to continue as a going concern. The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that may result from the outcome of this uncertainty.
Revenue Recognition, Policy [Policy Text Block]						Revenue Recognition
						The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Use of Estimates, Policy [Policy Text Block]	Use of estimates					Use of estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.					The preparation of financial statements in accordance with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the useful life of fixed assets and assumptions used in the fair value of stock-based compensation.
Concentration Risk, Credit Risk, Policy [Policy Text Block]						Concentrations of Credit Risk
						Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit.
Prepaid Expenses Policy [Policy Text Block]						Prepaid Expenses
						From time to time, the Company issues shares of its common stock for services to be performed.  The fair value of the common stock is determined at the date of the contract for services and is amortized ratably over the term of the contract.  As of December 31, 2014 and 2013, prepaid expenses relating to stock based payments were $56,667 and $-0-, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]						Property and Equipment
						Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]						Long-Lived Assets
						The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used.  Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset.  Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments					Fair Value of Financial Instruments
	The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.					The Company’s short-term financial instruments, including cash, prepaid expenses and other assets, accounts payable and accrued expenses and other liabilities, consist primarily of instruments without extended maturities, the fair value of which, based on management’s estimates, reasonably approximate their book value. The fair value of the Company’s convertible securities is based on management estimates and reasonably approximates their book value.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs					Research and development costs
	The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $302,079  and $122,151 for the three months ended March 31, 2015 and 2014, respectively.					The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $547,996  and $992,207 for the years ended December 31, 2014 and 2013, respectively.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share					Net Income (loss) Per Common Share
	The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.					The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year.  Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.
	The computation of basic and diluted loss per share as of March 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.					The computation of basic and diluted loss per share as of December 31, 2014 and 2013 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period.
	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:					Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,			2014		2013
		2015		2014		Series A convertible preferred stock		-		501,089
	Series A convertible preferred stock		-		501,089	Series B convertible preferred stock		-		451,726
	Series B convertible preferred stock		-		451,726	Series C convertible preferred stock		1,807,333		1,330,627
	Series C convertible preferred stock		1,640,667		1,854,019	Options to purchase common stock		5,990,190		2,990,977
	Options to purchase common stock		6,205,190		2,990,977	Warrants to purchase common stock		5,113,990		2,717,258
	Warrants to purchase common stock		7,561,820		4,353,831	Totals		12,911,513		7,991,667
	Totals		15,407,677		10,151,642
Income Tax, Policy [Policy Text Block]	Income Taxes					Income Taxes
						The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse.
	The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock Based Compensation					Stock Based Compensation
	The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.					The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period.
	As of March 31, 2015, the Company had 6,205,190 options outstanding to purchase shares of common stock, of which 4,130,240 were vested.					As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
	As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.					As of December 31, 2013, the Company had 2,990,977 options outstanding to purchase shares of common stock, of which 1,675,658 were vested.
Registration Rights Policy [Policy Text Block]	Registration Rights					Registration Rights
	The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements.					The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations.  On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission.  As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense for the liability under the registration rights agreements.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements					Recent Accounting Pronouncements
	There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.					There are various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company's financial position, results of operations or cash flows.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability
	The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At March 31, 2015 and December 31, 2014, the Company did not have any derivative instruments that were designated as hedges.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:					Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:
		March 31,		March 31,			2014		2013
		2015		2014		Series A convertible preferred stock		-		501,089
	Series A convertible preferred stock		-		501,089	Series B convertible preferred stock		-		451,726
	Series B convertible preferred stock		-		451,726	Series C convertible preferred stock		1,807,333		1,330,627
	Series C convertible preferred stock		1,640,667		1,854,019	Options to purchase common stock		5,990,190		2,990,977
	Options to purchase common stock		6,205,190		2,990,977	Warrants to purchase common stock		5,113,990		2,717,258
	Warrants to purchase common stock		7,561,820		4,353,831	Totals		12,911,513		7,991,667
	Totals		15,407,677		10,151,642

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended							12 Months Ended
	Mar. 31, 2015							Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of March 31, 2015 and December 31, 2014 is summarized as follows:							Property and equipment as of December 31, 2014 and 2013 is summarized as follows:
		March 31,			December 31,				2014			2013
		2015			2014			Computer equipment	$	54,900		$	50,937
	Computer equipment	$	57,584		$	54,900		Furniture and fixtures		7,803			7,803
	Furniture and fixtures		7,803			7,803		Subtotal		62,703			58,740
	Subtotal		65,387			62,703		Less accumulated depreciation		(49,683	)		(33,874	)
	Less accumulated depreciation		(52,543	)		(49,683	)	Property and equipment, net	$	13,020		$	24,866
	Property and equipment, net	$	12,844		$	13,020

ACCOUNTS_PAYABLE_AND_ACCRUED_E1

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended					12 Months Ended
	Mar. 31, 2015					Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at March 31, 2015 and December 31, 2014 consist of the following:					Accounts payable and accrued expenses at December 31, 2014 and 2013 consist of the following:
		March 31,		December 31,			2014		2013
		2015		2014		Accrued accounting and legal	$	190,767	$	300,893
	Accrued accounting and legal	$	71,952	$	190,767	Accrued reimbursements		26,792		17,797
	Accrued reimbursements		17,305		26,792	Accrued consulting		16,334		214,481
	Accrued consulting		82,935		16,334	Accrued research and development expenses		93,407		64,670
	Accrued research and development expenses		42,409		93,407	Accrued credit card obligations		13,278		20,425
	Accrued credit card obligations		4,735		13,278	Accrued payroll		62,068		35,896
	Accrued payroll		-		62,068	Accrued liquidated damages		55,620		48,668
	Accrued liquidated damages		55,620		55,620	Accrued office and other		29,093		16,500
	Accrued office and other		5,915		29,093	Accrued settlement related to arbitration		66,667		100,000
	Accrued settlement related to arbitration		40,000		66,667		$	554,026	$	819,330
		$	320,871	$	554,026

OPTIONS_AND_WARRANTS_Tables

OPTIONS AND WARRANTS (Tables)	3 Months Ended																12 Months Ended
	Mar. 31, 2015																Dec. 31, 2014
OPTIONS AND WARRANTS (Tables) [Line Items]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the three months ended March 31, 2015 is as follows:																A summary of the stock option activity and related information for the 2012 Plan for the year ended December 31, 2014 and 2013 is as follows:
											Weighted-Average																Weighted-Average
							Weighted-Average				Remaining				Aggregate								Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value				Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,990,190			$	2.25				6.7				3,267,692	Outstanding at January 1, 2013			1,298,927			$	2.04				6.85				-
	Grants			215,000				2.47				7				-	Grants			1,692,050				2.09				7				-
	Exercised																Exercised
	Canceled																Canceled
	Outstanding at March 31, 2015			6,205,190			$	2.26				6.4			$	1,098,888	Outstanding at December 31, 2013			2,990,977			$	2.05				6.02			$	-
	Exercisable at March 31, 2015			4,130,240			$	2.25				5.9			$	797,753	Grants			3,478,498			$	2.39				8.1			$	-
																	Exercised			-
																	Canceled			(479,285	)			(2.00	)
																	Outstanding at December 31,2014			5,990,190			$	2.25				6.65			$	3,267,692
																	Vested and expected to vest at December 31, 2014			5,990,190			$	2.25				6.65			$	3,267,692
																	Exercisable at December 31, 2014			3,799,559			$	2.24				5.91			$	2,111,368
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the granted options for three months ended March 31, 2015 was determined using the Black Scholes option pricing model with the following assumptions:																Dividend yield:		-0-	%
																	Volatility		110.70% to 115.03	%
	Dividend yield:			-0-	%												Risk free rate:		1.07% to 3.04	%
	Volatility		129.54% to 130.30		%												Expected life:		7 to 10 years
	Risk free rate:		1.19% to 1.79		%												Estimated fair value of the Company’s common stock		$2.09
	Expected life:		7 years														Dividend yield:		-0-	%
	Estimated fair value of the Company’s common stock		$	1.99 to $2.24													Volatility		119.43% to 129.88	%
	Estimated forfeiture rate			0	%												Risk free rate:		0.48% to 2.53	%
																	Expected life:		7 to 10 years
																	Estimated fair value of the Company’s common stock		$2.21 to $2.50
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at March 31, 2015:																The following table presents information related to stock options at December 31, 2014:
	Options Outstanding												Options Exercisable				Options Outstanding								Options Exercisable
									Weighted																Weighted
									Average				Exercisable												Average				Exercisable
	Exercise				Number of				Remaining Life				Number of				Exercise				Number of				Remaining Life				Number of
	Price				Options				In Years				Options				Price				Options				In Years				Options
	$	1.01-2.00				834,642				4.5				541,642			$	1.01-2.00				819,642				4.7				526,642
		2.01-2.50				5,370,548				6.7				3,588,598				2.01-2.50				5,170,548				7				3,272,917
						6,205,190				6.4				4,130,240								5,990,190				6.7				3,799,559
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:																The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2014:
	Exercise				Number			Expiration									Exercise			Number		Expiration
	Price				Outstanding			Date									Price			Outstanding		Date
	$	0.001				383,320		Jan-20									$	0.001		383,320		Jan-20
	$	1.5				3,721,518		February 2018 to September 2018									$	1.5		3,721,518		February 2018 to September 2018
	$	1.84				35,076		Jan-20									$	1.84		35,076		Jan-20
	$	2.02				30,755		Jan-20									$	2.02		30,755		Jan-20
	$	2.5				1,603,600		Jul-15									$	2.5		204,840		Jul-15
	$	2.75				228,720		August 2019 to September 2019									$	2.75		228,720		August 2019 to September 2019
	$	3.67				218,275		December 2018 to January 2019									$	3.67		218,275		December 2018 to January 2019
	$	3.75				1,340,556		April 2019 to March 2020									$	3.75		291,486		April 2019 to March 2020
						7,561,820														5,113,990
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the three months ended March 31, 2015 is as follows:																A summary of the warrant activity for the years ended December 31, 2014 and 2013 is as follows:
											Weighted-Average																Weighted-Average
							Weighted-Average				Remaining				Aggregate								Weighted-Average				Remaining				Aggregate
			Shares				Exercise Price				Contractual Term				Intrinsic Value				Shares				Exercise Price				Contractual Term				Intrinsic Value
	Outstanding at January 1, 2015			5,113,990			$	1.71				3.6				6,041,436	Outstanding at January 1, 2013			-			$	-				-				-
	Grants			2,447,830				3.04				2.4				-	Grants			2,717,258				2.28				7				-
	Exercised																Exercised
	Canceled																Canceled
	Outstanding at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	Outstanding at December 31, 2013			2,717,258			$	2.28				6.02			$	-
																	Grants			2,396,732			$	4.64				2.05			$	-
	Vested and expected to vest at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	Exercised			-
	Exercisable at March 31, 2015			7,561,820			$	2.14				3			$	4,300,280	Canceled			-				-
																	Outstanding at December 31,2014			5,113,990			$	1.71				3.6			$	6,041,436
																	Vested and expected to vest at December 31, 2014			5,113,990			$	1.71				3.6			$	6,041,436
																	Exercisable at December 31, 2014			5,113,990			$	1.71				3.6			$	6,041,436
Warrant [Member] | Series C Preferred Stock [Member]
OPTIONS AND WARRANTS (Tables) [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]																	The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
																	Dividend yield:			-0-	%
																	Volatility			125.33	%
																	Risk free rate:			1.4	%
																	Expected life:		5 years
																	Estimated fair value of the Company’s common stock		$	2.09
Warrant [Member] | Private Placement [Member]
OPTIONS AND WARRANTS (Tables) [Line Items]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]																	The fair value of the issued warrants were determined using the Black Scholes option pricing model with the following assumptions:
																	Dividend yield:			-0-	%
																	Volatility			123.3	%
																	Risk free rate:			0.72	%
																	Expected life:		5 years
																	Estimated fair value of the Company’s common stock		$	2.09

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The effective rate differs from the statutory rate of 34% for due to the following:
		2014			2013
	Statutory rate on pre-tax book  loss		(34.00	)%		(34.00	)%
	Stock based compensation		23	%		11.7	%
	Financing costs		2.4	%		2.4	%
	Valuation allowance		8.6	%		19.9	%
			0	%		0	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred taxes as of December 31, 2014 and 2013 consist of the following:
		2014			2013
	Non-Current deferred tax asset:
	Net operating loss carry-forwards	$	2,300,000		$	1,400,000
	Valuation allowance		(2,300,000	)		(1,400,000	)
	Net non-current deferred tax asset	$	-		$	-

FAIR_VALUE_MEASUREMENT_Tables

FAIR VALUE MEASUREMENT (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities as of March 31, 2015:
		Warrant		Derivative
		Liability
	Balance, December 31, 2014	$	-	$	-
	Total (gains) losses
	Initial fair value of derivative at March 31, 2015, reclassified from equity		—		1,242,590
	Initial fair value of warrant liability at March 31, 2015, reclassified from equity		4,097,444		—
	Balance, March 31, 2015	$	4,097,444	$	1,242,590

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)			$56,667	$0
Research and Development Expense (in Dollars)	302,079	122,151	547,996	992,207
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,205,190		5,990,190	2,990,977	1,298,927
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number			5,990,190
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)	$55,620		$55,620	$48,668
Employee Stock Option [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	6,205,190		5,990,190	2,990,977
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			3,799,559	1,675,658
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,130,240		3,799,559
Minimum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years		3 years
Maximum [Member]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years		5 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	15,407,677	10,151,642	12,911,513	7,991,667
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	501,089	0	501,089
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	451,726	0	451,726
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,640,667	1,854,019	1,807,333	1,330,627
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,205,190	2,990,977	5,990,190	2,990,977
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,561,820	4,353,831	5,113,990	2,717,258

GOING_CONCERN_MATTERS_Details

GOING CONCERN MATTERS (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Going Concern Disclosure [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	($3,132,301)	($1,201,558)	($8,773,399)	($10,101,846)
Net Cash Provided by (Used in) Operating Activities	($1,219,982)	($505,763)	($1,997,072)	($1,762,459)

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Jan. 31, 2014
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current	$0		$0	$30,781	$30,781
Debt Conversion, Original Debt, Amount	0	0	0	600,000
Class of Warrant or Rights, Granted (in Shares)	2,447,830		2,396,732	2,717,258
Stock Issued During Period, Shares, New Issues (in Shares)			956,179	122,449
Interest Payable, Related Party, Current			40,293	123,089	123,089
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized			56,667	0	0
Stock Issued During Period, Value, Other			65,000
Due to Other Related Parties, Classified, Current			11,250	0	0
Settlement of Related Party Debt [Member] | Director [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)			$2.50
Stock Issued During Period, Shares, Other (in Shares)			26,000
Stock Issued During Period, Value, Other			65,000
Board of Directors Chairman [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Original Debt, Amount					228,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					93,061
Class of Warrant or Rights, Granted (in Shares)					46,531
Investor [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)					61,225
Stock Issued During Period, Shares, New Issues (in Shares)					122,448
Proceeds from Issuance of Private Placement					300,000
Director [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)						12,246
Stock Issued During Period, Shares, New Issues (in Shares)						24,490
Proceeds from Issuance of Private Placement						60,000
Extinguishment of Debt, Amount			87,500
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures (in Shares)			34,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures			85,000
Shares Issued, Price Per Share (in Dollars per share)			$2.50
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized			$56,667
President and Director [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)				53,830
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$2.61	$2.61
Warrants, Term of Warrants				5 years

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$2,860	$4,435	$15,809	$17,059
Minimum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years		3 years
Maximum [Member]
PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years		5 years

PROPERTY_AND_EQUIPMENT_Details1

PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$65,387	$62,703	$58,740
Less accumulated depreciation	-52,543	-49,683	-33,874
Property and equipment, net	12,844	13,020	24,866
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	57,584	54,900	50,937
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$7,803	$7,803	$7,803

ACCOUNTS_PAYABLE_AND_ACCRUED_E2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$71,952	$190,767	$300,893
Accrued reimbursements	17,305	26,792	17,797
Accrued consulting	82,935	16,334	214,481
Accrued research and development expenses	42,409	93,407	64,670
Accrued credit card obligations	4,735	13,278	20,425
Accrued payroll	0	62,068	35,896
Accrued liquidated damages	55,620	55,620	48,668
Accrued office and other	5,915	29,093	16,500
Accrued settlement related to arbitration	40,000	66,667	100,000
	$320,871	$554,026	$819,330

NOTES_PAYABLE_RELATED_PARTY_De

NOTES PAYABLE, RELATED PARTY (Details) (USD $)	3 Months Ended	12 Months Ended		0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Dec. 06, 2012	Nov. 21, 2012
NOTES PAYABLE, RELATED PARTY (Details) [Line Items]
Class of Warrant or Rights, Granted	2,447,830	2,396,732	2,717,258
President [Member]
NOTES PAYABLE, RELATED PARTY (Details) [Line Items]
Debt Instrument, Face Amount					$30,000	$218,000
Debt Instrument, Maturity Date						21-Nov-21
Debt Instrument, Payment Terms						In connection with the issuance of the unsecured promissory note, the Company’s President agreed not to receive payments (by voluntary prepayment, acceleration, set-off or otherwise) associated with the unsecured promissory note absent the prior written consent of the purchasers holding at least 67% interest of the preferred stock outstanding, which purchasers must include Alpha Capital Anstalt so long as Alpha Capital Anstalt holds not less than $100,000 of preferred stock.
Debt Conversion, Converted Instrument, Shares Issued				93,061
Class of Warrant or Rights, Granted				46,531
Class of Warrant or Right, Exercise Price of Warrants or Rights			3.67	$3.67
Warrants, Term of Warrants				5 years
Debt Instrument, Interest Rate Terms					interest free
Debt Instrument, Maturity Date, Description					due the earlier of (i) the next financing of not less than $300,000; (ii) February 28, 2013 or (iii) occurrence of an event of default, as defined.

CONVERTIBLE_BRIDGE_NOTES_Detai

CONVERTIBLE BRIDGE NOTES (Details) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended		3 Months Ended	0 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Feb. 06, 2013	Jan. 09, 2013	Sep. 30, 2013	Aug. 07, 2013	Dec. 31, 2012	Feb. 28, 2014	Jan. 31, 2014
CONVERTIBLE BRIDGE NOTES (Details) [Line Items]
Class of Warrant or Rights, Granted	2,447,830		2,396,732	2,717,258
Debt Conversion, Original Debt, Amount	$0	$0	$0	$600,000
Series C Preferred Stock [Member] | Bridge Loan [Member]
CONVERTIBLE BRIDGE NOTES (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued					600
Class of Warrant or Rights, Granted					287,082
Class of Warrant or Right, Exercise Price of Warrants or Rights					$2.09
Warrants, Term of Warrants					5 years
Series C Preferred Stock [Member]
CONVERTIBLE BRIDGE NOTES (Details) [Line Items]
Class of Warrant or Rights, Granted			984,674	1,516,386		1,330,627	622,414
Class of Warrant or Right, Exercise Price of Warrants or Rights			$1.50	$2.61		$2.61				$1.50	$2.61
Warrants, Term of Warrants				5 years		5 years
Related Party [Member] | Bridge Loan [Member]
CONVERTIBLE BRIDGE NOTES (Details) [Line Items]
Debt Instrument, Face Amount									225,000
Bridge Loan [Member]
CONVERTIBLE BRIDGE NOTES (Details) [Line Items]
Debt Instrument, Face Amount									600,000
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Debt Instrument, Convertible, Terms of Conversion Feature									The Convertible Bridge Notes and any accrued and unpaid interest automatically converts at the earlier of (i) (A) a completion of a transaction whereby the Company merges or consolidates with another company that has its common stock approved for quotation on any domestic national stock exchange and (B) the new entity thereafter issues and sells shares for no less than $3.0 million aggregate gross proceeds or (ii) a qualified IPO. The Convertible Bridge Notes shall convert into the new securities issued at 95% of the purchase price of the Conversion Securities offered to investors.
Debt Instrument, Description									In connection with the issuance of the Senior Convertible Promissory Notes, the Company issued the right to purchase at any time, on or after the Public Financing Closing Date,(as defined above) hereof until the fifth anniversary of the Public Financing Closing date, the number of fully paid and nonassessable shares (the “Warrant Shares”) of the Company’s common stock equal to the quotient of (a) the Warrant Coverage Amount (as defined below), divided by (b) the applicable Conversion Price of the Notes, at the per share exercise price (the “Exercise Price”), which shall initially be, as of the Public Financing Closing Date, equal to the Initial Exercise Price (as defined below), subject to further adjustments, as defined.Initial Exercise Price” means one hundred twenty-five percent (125%) of the Conversion Price.Warrant Coverage Amount” shall be the amount obtained by multiplying (x) the Warrant Coverage Percentage by (y) the principal amount outstanding (and not including any accrued and unpaid interest) of the Note, in connection with which this Warrant is concurrently issued.“Warrant Coverage Percentage” shall be equal to fifty percent (50%) as defined in the Bridge Loan Agreement.
Debt Conversion, Converted Instrument, Shares Issued								8,941
Debt Conversion, Original Debt, Amount								$18,677

REDEEMABLE_PREFERRED_STOCK_Det

REDEEMABLE PREFERRED STOCK (Details) (USD $)	0 Months Ended	1 Months Ended	0 Months Ended
	Jun. 23, 2014	31-May-11	Nov. 28, 2011	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized				1,000,000	1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share				$0.00	$0.00	$0.00
Dividends Payable, Current				$456,964	$445,069	$414,967
Series A Preferred Stock [Member] | Other Current Liabilities [Member]
REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current						119,355
Series A Preferred Stock [Member]
REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized		200		200	200	200
Preferred Stock, Dividend Payment Terms		payable quarterly
Preferred Stock, Liquidation Preference, Value		5,000				922,000
Preferred Stock, Dividend Rate, Percentage		5.00%
Preferred Stock, Par or Stated Value Per Share		$5,000
Preferred Stock, Voting Rights		no voting rights
Preferred Stock, Redemption Date		31-Dec-14
Preferred Stock, Redemption Terms		The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
Preferred Stock Redemption, Percentage		14.00%
Preferred Stock, Redemption Price Per Share		$1.84
Preferred Stock, Shares Issued					184.4	184.4
Preferred Stock, Shares Outstanding						184.4
Conversion of Stock, Shares Issued	577,901
Conversion of Stock, Amount Converted	141,331
Series B Preferred Stock [Member] | Other Current Liabilities [Member]
REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current						88,872
Series B Preferred Stock [Member]
REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized			600	600	600	600
Preferred Stock, Dividend Payment Terms			payable quarterly
Preferred Stock, Liquidation Preference, Value			5,000			887,500
Preferred Stock, Dividend Rate, Percentage			5.00%
Preferred Stock, Par or Stated Value Per Share			$5,000
Preferred Stock, Voting Rights			no voting rights
Preferred Stock, Redemption Date			31-Dec-14
Preferred Stock, Redemption Terms			The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.
Preferred Stock Redemption, Percentage			14.00%
Preferred Stock, Redemption Price Per Share			$2.02
Preferred Stock, Shares Issued					177.5	177.5
Preferred Stock, Shares Outstanding						177.5
Conversion of Stock, Shares Issued	493,818
Conversion of Stock, Amount Converted	$110,026

SERIES_C_9_CONVERTIBLE_PREFERR1

SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) (USD $)	3 Months Ended	12 Months Ended			0 Months Ended		1 Months Ended				3 Months Ended	6 Months Ended	0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Feb. 06, 2013	Jan. 09, 2013	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Sep. 30, 2013	Jul. 31, 2013	Aug. 07, 2013	Feb. 28, 2014	Jan. 31, 2014
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)	2,447,830	2,396,732	2,717,258
Adjustments to Additional Paid in Capital, Other		$87,500
Adjustments to Additional Paid in Capital, Warrant Issued		52,800
Temporary Equity, Amortization Period			1 year
Stock Issued During Period, Shares, New Issues (in Shares)		956,179	122,449
Dividends Payable, Current	456,964	445,069	414,967	414,967			456,964		445,069
Registration Payment Arrangement, Term	The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.	The Company entered into a Registration Rights Agreement in connection with the sale and issuance of the Series C preferred stock. The Company is required to file a registration statement registering for resale the (a) common stock issuable upon conversion in full of the Preferred Stock (assuming on such date the shares of Preferred Stock are converted in full without regard to any conversion limitations therein), (b) all shares of Common Stock issuable as dividends and “Make-Whole Payments” (as defined in the Certificate of Designation) on the Preferred Stock assuming all dividend and Make-Whole Payments are made in shares of Common Stock and the Preferred Stock is held for at least 3 years, (c) all warrant shares then issuable upon exercise of the Warrants (assuming on such date the warrants are exercised in full without regard to any exercise limitations therein), (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the Preferred Stock or the Warrants (in each case, without giving effect to any limitations on conversion set forth in the Certificate of Designation or limitations on exercise set forth in the Warrants) and (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement and must be declared effective no later than 210 days from the date of termination of the sale the Series C preferred stock.The Company is required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company fails to comply with the registration statement effective date requirements, the Company is required to pay the investors a fee equal to 0.25% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 3% to each Purchaser.
Registration Payment Arrangement, Accrual Carrying Value	55,620	55,620	48,668	48,668			55,620		55,620
Embedded Derivative, Fair Value of Embedded Derivative Liability	1,242,590	0	0	0			1,242,590		0
Derivative Liability, Current	4,097,444	0	0	0			4,097,444		0
Warrant [Member] | Series C Preferred Stock [Member] | Minimum [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			0.39%
Fair Value Assumptions, Expected Volatility Rate			123.41%
Warrant [Member] | Series C Preferred Stock [Member] | Maximum [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate			1.40%
Fair Value Assumptions, Expected Volatility Rate			125.33%
Warrant [Member] | Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term			5 years
Fair Value Assumptions, Expected Dividend Rate			0.00%
Options Held [Member] | Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other				1,303,671
Temporary Equity, Liquidation Preference			1,303,671	1,303,671
Warrant [Member] | Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued				1,064,739
Temporary Equity, Liquidation Preference			1,064,739	1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference			412,590	412,590
Series C Preferred Stock [Member] | Common Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Redemption Price Per Share (in Dollars per share)		$1.50							$1.50
Series C Preferred Stock [Member] | Dividend Declared [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current		445,069	206,740	206,740					445,069
Series C Preferred Stock [Member] | Bridge Loan [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted (in Shares)					287,082
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)					$2.09
Warrants, Term of Warrants					5 years
Debt Conversion, Converted Instrument, Shares Issued (in Shares)					600
Series C Preferred Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized (in Shares)		4,200				4,200			4,200
Preferred Stock, Dividend Rate, Percentage	9.00%	9.00%	9.00%			9.00%
Temporary Equity, Par Value						1,000
Preferred Stock, Dividend Payment Terms						payable quarterly
Preferred Stock, Voting Rights						no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series C preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series C preferred stock or alter or amend the Certificate of Designation
Temporary Equity, Redemption Price Per Share (in Dollars per share)						$1.50
Preferred Stock, Redemption Terms						(i) the greater of 120% of the stated value of $1,000 or the product of the variable weighted average price of the Company’s common stock on the trading day immediately preceding the date of the triggering event and the stated value divided by the then conversion price or (ii) either (a) redeem each Series C preferred share for a redemption price, in shares of the Company’s common stock, equal to a number of shares equal to the (i) above divided by 75%.
Class of Warrant or Rights, Granted (in Shares)		984,674	1,516,386			1,330,627					622,414
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$1.50	$2.61	$2.61		$2.61			$1.50					$1.50	$2.61
Warrants, Term of Warrants			5 years			5 years
Warrant, Description of Warrant						after the six month anniversary of the initial exercise date, there is no effective registration statement registering, or no current prospectus available for the resale of the warrant shares by the holder, then the warrant may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in which the holder shall be entitled to receive a number of Warrant Shares equal to defined formula.
Adjustments to Additional Paid in Capital, Warrant Issued			1,074,833
Temporary Equity, Liquidation Preference	2,461,000	2,711,000	2,781,000	2,781,000			2,461,000		2,711,000
Stock Issued During Period, Shares, New Issues (in Shares)												2,181
Proceeds from Issuance of Redeemable Preferred Stock												$1,814,910
Conversion of Stock, Shares Issued (in Shares)							169,334	42,334	59,267	59,267
Conversion of Stock, Shares Converted (in Shares)							200	50	70	70
Temporary Equity, Shares Outstanding (in Shares)	2,461	2,711	2,781	2,781			2,461		2,711
Preferred Stock, Shares Issued (in Shares)	2,461	2,711					2,461		2,711
Common Stock [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)	1,398,760	956,179	122,449
Bridge Loan [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)													8,941
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term	2 years 284 days
Fair Value Assumptions, Risk Free Interest Rate	0.56%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term	3 years 6 months
Fair Value Assumptions, Risk Free Interest Rate	0.89%
Embedded Derivative Financial Instruments [Member]
SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	141.00%

STOCKHOLDER_EQUITY_Details

STOCKHOLDER EQUITY (Details) (USD $)	3 Months Ended		12 Months Ended		0 Months Ended		1 Months Ended				6 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2014	Jun. 23, 2014	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Jul. 31, 2013	31-May-11	Nov. 28, 2011	Jan. 09, 2013
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000		1,000,000	1,000,000			1,000,000		1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00		$0.00	$0.00			0.001		0.001
Common Stock, Shares Authorized	50,000,000		50,000,000	50,000,000			50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$0.00		$0.00	$0.00			0.001		0.001
Common Stock, Shares, Issued	13,159,694		11,179,266	8,412,101			13,159,694		11,179,266
Common Stock, Shares, Outstanding	13,159,694		11,179,266	8,412,101			13,159,694		11,179,266
Stock Issued During Period, Value, Issued for Services (in Dollars)	$928,900		$1,635,000	$44,751
Stock Issued During Period, Shares, New Issues			956,179	122,449
Proceeds from Issuance of Common Stock (in Dollars)	3,042,213	229,222	1,969,410	299,974
Stock Issued During Period, Value, Other (in Dollars)			65,000
Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance			417,500						417,500
Deferred Compensation Liability, Current (in Dollars)	646,066		226,305	0			646,066		226,305
Deferred Compensation Arrangement with Individual, Exercise Price (in Dollars per share)			$2.50
Proceeds from Issuance or Sale of Equity (in Dollars)	3,042,213
Common Stock, Shares Subscribed but Unissued	352,500						352,500
Stock Issued for Services [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services				21,412
Stock Issued During Period, Value, Issued for Services (in Dollars)				44,751
Shares Issued, Price Per Share (in Dollars per share)				$2.09
Settlement of Related Party Debt [Member] | Director [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)			$2.50						2.5
Stock Issued During Period, Shares, Other			26,000
Stock Issued During Period, Value, Other (in Dollars)			65,000
Investor [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars)			1,969,410
Director [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)			$2.50						2.5
Stock Issued During Period, Shares, New Issues					24,490
Proceeds from Issuance of Common Stock (in Dollars)				247,174
Sale of Stock, Price Per Share (in Dollars per share)				$2.45
Proceeds from Issuance of Private Placement (in Dollars)					60,000
Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services	370,000
Stock Issued During Period, Value, Issued for Services (in Dollars)	928,900
Shares Issued, Price Per Share (in Dollars per share)	$2.51		$2.50				2.51		2.5
Stock Issued During Period, Shares, Share-based Compensation, Gross			654,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)			$1,635,000
Series A Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	200		200	200			200		200			200
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)												$5,000
Preferred Stock, Shares Issued			184.4	184.4					184.4
Stock Issued During Period, Shares, Conversion of Convertible Securities						577,901
Conversion of Stock, Shares Issued						577,901
Preferred Stock, Shares Outstanding				184.4
Series B Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	600		600	600			600		600				600
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)													$5,000
Preferred Stock, Shares Issued			177.5	177.5					177.5
Stock Issued During Period, Shares, Conversion of Convertible Securities						493,818
Conversion of Stock, Shares Issued						493,818
Preferred Stock, Shares Outstanding				177.5
Series C Preferred Stock [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized	4,200		4,200	4,200			4,200		4,200
Preferred Stock, Shares Issued	2,461		2,711				2,461		2,711
Temporary Equity, Shares Authorized			4,200						4,200					4,200
Temporary Equity, Shares Issued	2,461		2,711	2,781			2,461		2,711
Conversion of Stock, Shares Issued							169,334	42,334	59,267	59,267
Conversion of Stock, Shares Converted							200	50	70	70
Stock Issued During Period, Shares, New Issues											2,181
Preferred Stock, Shares Outstanding	2,461		2,711				2,461		2,711
Private Placement [Member]
STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,398,760
Securities Purchase Agreement	In connection with the securities purchase agreements described above, the Company entered into a registration rights agreement whereas the Company is required to file a registration statement registering for resale the a) all of the purchase agreement Shares, (b) all investor warrant Shares then issuable upon exercise of the investor warrants, (c) the shares of common stock underlying the investment banker warrants; (d) any additional shares of Common Stock issuable in connection with any anti-dilution provisions in the investor warrants and the investment banker warrants (e) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. The Company is required to file a registration statement the 45 days following the final closing date and must be declared effective no later than 180 days from the filing date.The Company was required to maintain the effectiveness of the registration statement from its effective date unless all securities registered under the registration statement have been sold or are otherwise able to be sold. If the Company failed to comply with the registration statement filing and effective date requirements, the Company is required to pay the investors a fee equal to 1% of the Purchaser’s investment, for each 30-day period of delay, subject to a maximum payment of 6% to each Purchaser.

OPTIONS_AND_WARRANTS_Details

OPTIONS AND WARRANTS (Details) (USD $)	3 Months Ended	12 Months Ended		0 Months Ended	3 Months Ended	1 Months Ended			0 Months Ended						1 Months Ended	0 Months Ended	1 Months Ended		3 Months Ended	0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jan. 09, 2013	Sep. 30, 2013	Jul. 31, 2014	Oct. 31, 2014	Sep. 30, 2014	Jan. 31, 2014	Jan. 13, 2013	Mar. 31, 2015	Feb. 27, 2015	Feb. 10, 2015	Jan. 23, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Apr. 30, 2014	Mar. 31, 2014	Oct. 19, 2012	Dec. 31, 2012	Feb. 28, 2014	Jul. 31, 2012
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	215,000	3,478,498	1,692,050
Share Price (in Dollars per share)	$2.40	$2.09									$2.40				$2.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Forfeiture Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		5,990,190													5,990,190
Class of Warrant or Rights, Granted	2,447,830	2,396,732	2,717,258
Class of Warrant or Right, Outstanding	7,561,820	5,113,990	2,717,258								7,561,820				5,113,990	2,717,258					0
Series C Preferred Stock [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted		984,674	1,516,386	1,330,627	622,414
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$1.50	2.61	$2.61					2.61						$1.50	$2.61						$1.50
Warrants, Term of Warrants			5 years	5 years
Warrants, Fair Value of Warrants, Granted (in Dollars)			1,074,833
Class of Warrant or Right, Outstanding									2,138,800													3,721,518
Directors and Key Consultants [Member] | Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		3,478,498
Directors and Key Consultants [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	200,000
Stock Issued During Period, Shares, Share-based Compensation, Gross		654,000
Stock Issued During Period, Shares, Issued for Services	370,000
Chief Executive Officer [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares						45,206
Chief Executive Officer [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						497,267
Chief Executive Officer [Member] | Employee Stock Option [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						1,265,769
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)						2.21
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						vesting quarterly
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value (in Dollars)						2,383,443
Employees and Key Consultants [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							841,777	605,000
Employees and Key Consultants [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares							11,667
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights							based on future performance conditions
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number								125,000
Employees and Key Consultants [Member] | Employee Stock Option [Member] | Share-based Compensation Award, Tranche Three [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number								150,000
Employees and Key Consultants [Member] | Employee Stock Option [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							853,444	880,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)							2.5	2.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value (in Dollars)							1,339,151	1,753,616
Director [Member] | Employee Stock Option [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							163,444	479,285
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)							2.5	2.5															$2
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights								vesting quarterly
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value (in Dollars)								981,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period								479,285
Stock Repurchased and Retired During Period, Shares							125,000
Director [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted									12,246
Private Placement [Member] | Warrants at $1.84 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted										35,076
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$1.84
Private Placement [Member] | Warrants at $2.02 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted										30,775
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)										$2.02
Private Placement [Member] | Warrants at $3.75 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted											307,770	167,250	252,750	321,300	153,630
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$3.75	$3.75									$3.75	$3.75	$3.75	$3.75	$3.75
Warrant, Expriation Date											31-Mar-20	31-Mar-20	31-Mar-20	31-Mar-20	31-Mar-20
Private Placement [Member] | Warrants at $2.50 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted											410,360	223,000	337,000	428,400	204,840
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.50	$2.50									$2.50	$2.50	$2.50	$2.50	$2.50
Warrants, Term of Warrants															6 months
Warrant, Expriation Date											31-Jul-15	31-Jul-15	31-Jul-15	31-Jul-15
Private Placement [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	$2.40	$2.80									$2.40				$2.80
Class of Warrant or Rights, Granted								93,600	64,626	65,831					358,470	129,307	135,120	137,856
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			3.67					2.75	3.67							$3.67	$2.75	$3.75
Warrants, Term of Warrants								5 years	5 years	5 years						5 years	5 years	5 years
Warrants, Fair Value of Warrants, Granted (in Dollars)										115,854
Warrants at $1.84 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$1.84	$1.84									$1.84				$1.84
Class of Warrant or Right, Outstanding	35,076	35,076									35,076				35,076
Warrants at $2.02 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.02	$2.02									$2.02				$2.02
Class of Warrant or Right, Outstanding	30,755	30,755									30,755				30,755
Warrants at $3.75 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$3.75	$3.75									$3.75				$3.75
Class of Warrant or Right, Outstanding	1,340,556	291,486									1,340,556				291,486
Warrants at $2.50 [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$2.50	$2.50									$2.50				$2.50
Class of Warrant or Right, Outstanding	1,603,600	204,840									1,603,600				204,840
Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)		3,778,589													3,778,589
Employee Stock Option [Member] | Share-based Compensation Award, Tranche One [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	15,000		1,095,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	vesting immediately
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Two [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years		3 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			145,833													145,833
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	50% for the first and second anniversary
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Three [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			9 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			30,000													30,000
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Four [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			1 year
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			283,300													283,300
Employee Stock Option [Member] | Share-based Compensation Award, Tranche Five [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares			137,917													137,917
Employee Stock Option [Member] | Maximum [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)	$2.50										$2.50
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Employee Stock Option [Member] | Minimum [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)	$2										$2
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			7 years
Employee Stock Option [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	215,000		1,692,050
Share Price (in Dollars per share)		$2.80													$2.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Forfeiture Rate		0.00%
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)			2.09													$2.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value (in Dollars)		4,193,425	3,247,187
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)	1,970,428		862,066								1,970,428					862,066
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)	$798,789																		$343,837
Employee Stock Option [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		3,799,559	1,675,658
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,130,240	3,799,559									4,130,240				3,799,559
Maximum [Member] | 2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																				10 years
Maximum [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	$2.24		2.5								$2.24					$2.50
Minimum [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)	$1.99		2.21								$1.99					$2.21
2012 Equity Incentive Plan [Member]
OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				8,806,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award																				However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Common Stock, Capital Shares Reserved for Future Issuance																				1,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Forfeiture Rate			0.00%

OPTIONS_AND_WARRANTS_Details_S

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	6,205,190	5,990,190	2,990,977	1,298,927
Options Outstanding, Weighted-Average Exercise Price	$2.26	$2.25	$2.05	$2.04
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 146 days	6 years 237 days	6 years 7 days	6 years 310 days
Options Outstanding, Aggregate Intrinsic Value	$1,098,888	$3,267,692	$0	$0
Vested and expected to vest at December 31, 2014		5,990,190
Vested and expected to vest at December 31, 2014		$2.25
Vested and expected to vest at December 31, 2014		6 years 237 days
Vested and expected to vest at December 31, 2014		3,267,692
Exercisable at December 31, 2014	4,130,240	3,799,559
Exercisable at December 31, 2014	$2.25	$2.24
Exercisable at December 31, 2014	5 years 328 days	5 years 332 days
Exercisable at December 31, 2014	$797,753	$2,111,368
Options Granted, Shares	215,000	3,478,498	1,692,050
Options Granted, Weighted-Average Exercise Price	$2.47	$2.39	$2.09
Options Granted, Weighted-Average Remaining Contractual Term	7 years	8 years 36 days	7 years
Options Exercised, Shares	0	0	0
Options Exercised, Weighted-Average Exercise Price	$0	$0	$0
Options Canceled, Shares	0	-479,285	0
Options Canceled, Weighted-Average Exercise Price	$0	($2)	$0

OPTIONS_AND_WARRANTS_Details_S1

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield:	0.00%	0.00%	0.00%
Expected life:	7 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.40	$2.09
Minimum [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	129.54%	110.70%	119.43%
Risk free rate:	1.19%	1.07%	0.48%
Expected life:		7 years	7 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$1.99		2.21
Maximum [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	130.30%	115.03%	129.88%
Risk free rate:	1.79%	3.04%	2.53%
Expected life:		10 years	10 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.24		2.5

OPTIONS_AND_WARRANTS_Details_S2

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding		5,990,190
Options Exercisable, Weighted Average Remaining Life		6 years 255 days
Number of Options Exercisable	4,130,240	3,799,559
Options at $1.01-2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Limit (in Dollars per share)	$1.01	$1.01
Exercise Price, Upper Limit (in Dollars per share)	$2	$2
Number of Options Outstanding		819,642
Options Exercisable, Weighted Average Remaining Life		4 years 255 days
Number of Options Exercisable	541,642	526,642
Options at $2.01-2.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Price, Lower Limit (in Dollars per share)	$2.01	$2.01
Exercise Price, Upper Limit (in Dollars per share)	$2.50	$2.50
Number of Options Outstanding		5,170,548
Options Exercisable, Weighted Average Remaining Life		7 years
Number of Options Exercisable	3,588,598	3,272,917

OPTIONS_AND_WARRANTS_Details_S3

OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Number of Warrants Outstanding	7,561,820	5,113,990	2,717,258	0
Warrants at $0.001 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$0.00	$0.00
Number of Warrants Outstanding	383,320	383,320
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $1.50 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.50	$1.50
Number of Warrants Outstanding	3,721,518	3,721,518
Expiration Date, Warrants	February 2018 to September 2018	February 2018 to September 2018
Warrants at $1.84 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.84	$1.84
Number of Warrants Outstanding	35,076	35,076
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $2.02 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.02	$2.02
Number of Warrants Outstanding	30,755	30,755
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $2.50 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.50	$2.50
Number of Warrants Outstanding	1,603,600	204,840
Expiration Date, Warrants	Jul-15	Jul-15
Warrants at $2.75 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.75	$2.75
Number of Warrants Outstanding	228,720	228,720
Expiration Date, Warrants	August 2019 to September 2019	August 2019 to September 2019
Warrants at $3.67 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.67	$3.67
Number of Warrants Outstanding	218,275	218,275
Expiration Date, Warrants	December 2018 to January 2019	December 2018 to January 2019
Warrants at $3.75 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.75	$3.75
Number of Warrants Outstanding	1,340,556	291,486
Expiration Date, Warrants	April 2019 to March 2020	April 2019 to March 2020

OPTIONS_AND_WARRANTS_Details_S4

OPTIONS AND WARRANTS (Details) - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.09	$2.40
Warrant [Member] | Private Placement [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield:	0.00%
Volatility	123.30%
Risk free rate:	0.72%
Expected life:	5 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.09
Private Placement [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.80	$2.40

OPTIONS_AND_WARRANTS_Details_S5

OPTIONS AND WARRANTS (Details) - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 31, 2015	Dec. 31, 2014
OPTIONS AND WARRANTS (Details) - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Estimated fair value of the Companybs common stock (in Dollars per share)		$2.40	$2.09
Warrant [Member] | Series C Preferred Stock [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield:	0.00%
Volatility	125.33%
Risk free rate:	1.40%
Expected life:	5 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.09

OPTIONS_AND_WARRANTS_Details_S6

OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	7,561,820	5,113,990	2,717,258	0
Warrants Outstanding, Weighted-Average Exercise Price	$2.14	$1.71	$2.28	$0
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years	3 years 219 days	6 years 7 days	0 years
Warrants Outstanding, Aggregate Intrinsic Value	$4,300,280	$6,041,436	$0	$0
Vested and expected to vest at December 31, 2014	7,561,820	5,113,990
Vested and expected to vest at December 31, 2014	$2.14	$1.71
Vested and expected to vest at December 31, 2014	3 years	3 years 219 days
Vested and expected to vest at December 31, 2014	4,300,280	6,041,436
Exercisable at December 31, 2014	7,561,820	5,113,990
Exercisable at December 31, 2014	$2.14	$1.71
Exercisable at December 31, 2014	3 years	3 years 219 days
Exercisable at December 31, 2014	$4,300,280	$6,041,436
Warrants Granted, Shares	2,447,830	2,396,732	2,717,258
Warrants Granted, Weighted-Average Exercise Price	$3.04	$4.64	$2.28
Warrants Granted, Weighted-Average Remaining Contractual Term	2 years 146 days	2 years 18 days	7 years
Warrants Exercised, Shares	0	0	0
Warrants Exercised, Weighted-Average Exercise Price	$0	$0	$0
Warrants Canceled, Shares	0	0	0
Warrants Canceled, Weighted-Average Exercise Price	$0	$0	$0

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$1,242,590	$0	$0
Derivative Liability, Current	$4,097,444	$0	$0

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	0 Months Ended		3 Months Ended	12 Months Ended		0 Months Ended
	31-May-14	Jan. 07, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Jul. 15, 2014
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Lessee Leasing Arrangements, Operating Leases, Term of Contract	3 years
Lessee Leasing Arrangements, Operating Leases, Renewal Term	1 year
Operating Leases, Rent Expense, Minimum Rentals	$6,530
Number of Directors						8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			215,000	3,478,498	1,692,050
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number				5,990,190
Loss Contingency, Damages Sought		Mr. Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
Loss Contingency, Settlement Agreement, Terms				Company settled the above claim for $100,000 with payments over six months
Litigation Settlement, Amount				100,000
Settlement Liabilities, Current			40,000	66,667	100,000
Options Vesting in Eleven Equal Installments [Member] | Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						45,206
Final Installment of Vested Options [Member] | Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						45,207
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche One [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number						542,473
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Two [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Three [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Four [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Share-based Compensation Award, Tranche Five [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares						180,824
Chief Executive Officer [Member] | Employee Agreement [Member] | Minimum [Member] | Annual Salary [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment						275,000
Chief Executive Officer [Member] | Employee Agreement [Member] | Minimum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Qualified Financing Amount						3,500,000
Chief Executive Officer [Member] | Employee Agreement [Member] | Maximum [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment						325,000
Chief Executive Officer [Member] | Employee Agreement [Member] | Signing Bonus [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment						30,000
Chief Executive Officer [Member] | Employee Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitments, Description						(i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						1,265,769
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price						2.21
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
Chief Executive Officer [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Compensation Arrangement with Individual, Requisite Service Period						3 years
Severance Agreement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought, Value				$6

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$6,800,000
Operating Loss Carryforwards, Expiration Date 1	2034
Deferred Tax Assets, Valuation Allowance	$2,300,000	$1,400,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%

INCOME_TAXES_Details_Schedule_

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Statutory rate on pre-tax book loss	-34.00%	-34.00%
Stock based compensation	23.00%	11.70%
Financing costs	2.40%	2.40%
Valuation allowance	8.60%	19.90%
	0.00%	0.00%

INCOME_TAXES_Details_Schedule_1

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
Non-Current deferred tax asset:
Net operating loss carry-forwards	$2,300,000	$1,400,000
Valuation allowance	-2,300,000	-1,400,000
Net non-current deferred tax asset	$0	$0

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)	3 Months Ended	12 Months Ended		1 Months Ended	0 Months Ended				1 Months Ended				3 Months Ended	6 Months Ended	0 Months Ended				1 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2015	Apr. 09, 2015	Jan. 31, 2014	Jan. 13, 2015	Jan. 09, 2013	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Oct. 31, 2014	Sep. 30, 2013	Jul. 31, 2013	Feb. 10, 2015	Jan. 23, 2015	Dec. 31, 2013	Jan. 13, 2013	Sep. 30, 2014	Aug. 31, 2014	Apr. 30, 2014	Feb. 28, 2014
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues		956,179	122,449
Class of Warrant or Rights, Granted	2,447,830	2,396,732	2,717,258
Proceeds from Issuance or Sale of Equity (in Dollars)	$3,042,213
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	215,000	3,478,498	1,692,050
Class of Warrant or Rights, Exercised	0	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0	0
Stock Issued to Consultants [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services				50,000
Director [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services				200,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					300,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)					$3.99
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period					7 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					vesting immediately upon appointment of a new board of directors member
Director [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues						24,490
Class of Warrant or Rights, Granted						12,246
Series C Preferred Stock [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued				131,234			42,334
Conversion of Stock, Shares Converted				155			50
Series C Preferred Stock [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued									169,334	42,334	59,267	59,267
Conversion of Stock, Shares Converted									200	50	70	70
Stock Issued During Period, Shares, New Issues														2,181
Class of Warrant or Rights, Granted		984,674	1,516,386					1,330,627					622,414
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1.5	2.61			2.61		$2.61			$1.50						$2.61					$1.50
Private Placement [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Warrant, Expriation Date															21-Mar-20	21-Mar-20
Class of Warrant or Rights, Granted															84,250	91,300
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)															$3.75	$3.75
Private Placement [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	1,398,760
Class of Warrant or Rights, Granted						64,626					358,470						129,307	65,831	93,600	135,120	137,856
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			3.67			3.67											$3.67		$2.75	$2.75	$3.75
Series A Warrants [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Warrant, Expriation Date															31-Jul-15	31-Jul-15
Class of Warrant or Rights, Granted															337,000	365,200
Proceeds from Issuance or Sale of Equity (in Dollars)															842,500	913,000
Series B Warrants [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Warrant, Expriation Date															21-Mar-20	21-Mar-20
Class of Warrant or Rights, Granted															168,500	182,600
Proceeds from Issuance or Sale of Equity (in Dollars)															$731,400	$917,480
Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services										302,500
Stock Issued During Period, Shares, New Issues															337,000	365,200
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				1.5
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)				2.09
Stock Issued During Period, Shares, Conversion of Convertible Securities				84,033
Class of Warrant or Rights, Exercised				130,084
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				10,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	3 Months Ended		12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	15,407,677	10,151,642	12,911,513	7,991,667
Series A Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	501,089	0	501,089
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	0	451,726	0	451,726
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	1,640,667	1,854,019	1,807,333	1,330,627
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	6,205,190	2,990,977	5,990,190	2,990,977
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,561,820	4,353,831	5,113,990	2,717,258

PROPERTY_AND_EQUIPMENT_Details2

PROPERTY AND EQUIPMENT (Details) - Property, Plant and Equipment (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$65,387	$62,703	$58,740
Less accumulated depreciation	-52,543	-49,683	-33,874
Property and equipment, net	12,844	13,020	24,866
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	57,584	54,900	50,937
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$7,803	$7,803	$7,803

NOTE_3_ACCOUNTS_PAYABLE_AND_AC

NOTE 3 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities (USD $)	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$71,952	$190,767	$300,893
Accrued reimbursements	17,305	26,792	17,797
Accrued consulting	82,935	16,334	214,481
Accrued research and development expenses	42,409	93,407	64,670
Accrued credit card obligations	4,735	13,278	20,425
Accrued payroll	0	62,068	35,896
Accrued liquidated damages	55,620	55,620	48,668
Accrued office and other	5,915	29,093	16,500
Accrued settlement related to arbitration	40,000	66,667	100,000
	$320,871	$554,026	$819,330

WARRANT_AND_DERIVATIVE_LIABILI1

WARRANT AND DERIVATIVE LIABILITIES (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	1,242,590	$0	$0
Derivative Liability, Current (in Dollars)	4,097,444	$0	$0
Embedded Derivative Financial Instruments [Member] | Minimum [Member]
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	0.56%
Embedded Derivative Financial Instruments [Member] | Maximum [Member]
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	0.89%
Embedded Derivative Financial Instruments [Member]
WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Expected Dividend Rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	141.00%

OPTIONS_AND_WARRANTS_Details_S7

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	6,205,190	5,990,190	2,990,977	1,298,927
Options Outstanding, Weighted Average Remaining Life	6 years 146 days	6 years 237 days	6 years 7 days	6 years 310 days
Options Exercisable, Number of Options	4,130,240	3,799,559
Options at $1.01-2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Exercisable, Exercise Price, Lower Range Limit (in Dollars per share)	1.01	1.01
Options Exercisable, Exercise Price, Upper Range Limit (in Dollars per share)	2	2
Options Outstanding, Number of Options	834,642
Options Outstanding, Weighted Average Remaining Life	4 years 6 months
Options Exercisable, Number of Options	541,642	526,642
Options at $2.01-2.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Exercisable, Exercise Price, Lower Range Limit (in Dollars per share)	2.01	2.01
Options Exercisable, Exercise Price, Upper Range Limit (in Dollars per share)	2.5	2.5
Options Outstanding, Number of Options	5,370,548
Options Outstanding, Weighted Average Remaining Life	6 years 255 days
Options Exercisable, Number of Options	3,588,598	3,272,917

OPTIONS_AND_WARRANTS_Details_S8

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	6,205,190	5,990,190	2,990,977	1,298,927
Options Outstanding, Weighted-Average Exercise Price	$2.26	$2.25	$2.05	$2.04
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 146 days	6 years 237 days	6 years 7 days	6 years 310 days
Options Outstanding, Aggregate Intrinsic Value	$1,098,888	$3,267,692	$0	$0
Exercisable at March 31, 2015	4,130,240	3,799,559
Exercisable at March 31, 2015	$2.25	$2.24
Exercisable at March 31, 2015	5 years 328 days	5 years 332 days
Exercisable at March 31, 2015	$797,753	$2,111,368
Grants	215,000	3,478,498	1,692,050
Grants	$2.47	$2.39	$2.09
Grants	7 years	8 years 36 days	7 years
Exercised	0	0	0
Exercised	$0	$0	$0
Canceled	0	-479,285	0
Canceled	$0	($2)	$0

OPTIONS_AND_WARRANTS_Details_S9

OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield:	0.00%	0.00%	0.00%
Expected life:	7 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.40	$2.09
Estimated forfeiture rate	0.00%
Minimum [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	129.54%	110.70%	119.43%
Risk free rate:	1.19%	1.07%	0.48%
Expected life:		7 years	7 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$1.99		2.21
Maximum [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	130.30%	115.03%	129.88%
Risk free rate:	1.79%	3.04%	2.53%
Expected life:		10 years	10 years
Estimated fair value of the Companybs common stock (in Dollars per share)	$2.24		2.5

Recovered_Sheet1

OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Number of Warrants Outstanding	7,561,820	5,113,990	2,717,258	0
Warrants at $0.001 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$0.00	$0.00
Number of Warrants Outstanding	383,320	383,320
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $1.50 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.50	$1.50
Number of Warrants Outstanding	3,721,518	3,721,518
Expiration Date, Warrants	February 2018 to September 2018	February 2018 to September 2018
Warrants at $1.84 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$1.84	$1.84
Number of Warrants Outstanding	35,076	35,076
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $2.02 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.02	$2.02
Number of Warrants Outstanding	30,755	30,755
Expiration Date, Warrants	Jan-20	Jan-20
Warrants at $2.50 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.50	$2.50
Number of Warrants Outstanding	1,603,600	204,840
Expiration Date, Warrants	Jul-15	Jul-15
Warrants at $2.75 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$2.75	$2.75
Number of Warrants Outstanding	228,720	228,720
Expiration Date, Warrants	August 2019 to September 2019	August 2019 to September 2019
Warrants at $3.67 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.67	$3.67
Number of Warrants Outstanding	218,275	218,275
Expiration Date, Warrants	December 2018 to January 2019	December 2018 to January 2019
Warrants at $3.75 [Member]
OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block] [Line Items]
Exercise Price, Warrants (in Dollars per share)	$3.75	$3.75
Number of Warrants Outstanding	1,340,556	291,486
Expiration Date, Warrants	April 2019 to March 2020	April 2019 to March 2020

Recovered_Sheet2

OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares	7,561,820	5,113,990	2,717,258	0
Warrants Outstanding, Weighted-Average Exercise Price	$2.14	$1.71	$2.28	$0
Warrants Outstanding, Weighted-Average Remaining Contractual Term	3 years	3 years 219 days	6 years 7 days	0 years
Warrants Outstanding, Aggregate Intrinsic Value	$4,300,280	$6,041,436	$0	$0
Vested and expected to vest at March 31, 2015	7,561,820	5,113,990
Vested and expected to vest at March 31, 2015	$2.14	$1.71
Vested and expected to vest at March 31, 2015	3 years	3 years 219 days
Vested and expected to vest at March 31, 2015	4,300,280	6,041,436
Exercisable at March 31, 2015	7,561,820	5,113,990
Exercisable at March 31, 2015	$2.14	$1.71
Exercisable at March 31, 2015	3 years	3 years 219 days
Exercisable at March 31, 2015	$4,300,280	$6,041,436
Grants	2,447,830	2,396,732	2,717,258
Grants	$3.04	$4.64	$2.28
Grants	2 years 146 days	2 years 18 days	7 years
Exercised	0	0	0
Exercised	$0	$0	$0
Canceled	0	0	0
Canceled	$0	$0	$0

FAIR_VALUE_MEASUREMENT_Details

FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (USD $)	3 Months Ended
	Mar. 31, 2015
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014	$0
Initial fair value of derivative reclassified from equity	4,097,444
Balance, March 31, 2015	4,097,444
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014	0
Initial fair value of derivative reclassified from equity	1,242,590
Balance, March 31, 2015	$1,242,590